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The original project titled ‘An investigation into the socio-demographic, clinical and 
psychological variables associated with psychological adjustment and health-related 
quality of life in Implantable Cardioverter Defibrillator (ICD) recipients’ (See original 
project proposal in Appendix 2.1, p.142-158) had to be abandoned.  
 
An ethics application based on this proposal had been completed and was due to be 
submitted on the Integrated Research Application System (IRAS). Nevertheless, this 
coincided with the first wave of the COVID-19 pandemic.  
 
Unfortunately, the original project could not go ahead as planned because data collection 
would have involved attending outpatient clinics to recruit ICD-recipients. During the 
first wave of the pandemic, some health boards suspended routine clinical activity and a 
proportion of the health care staff identified to facilitate the author’s access to participants 
had been redeployed. Additionally, the target population included individuals with 
various cardiac conditions and physical health comorbidities. Therefore, potential 
participants fell under the ‘clinically vulnerable’ group, who were asked to shield at home 
and avoid unnecessary social contact between March and July 2020.  
 
As a result of these circumstances, it was agreed by the author and research supervisors 
to abandon the original project. The author’s field and research supervisors - Dr John 
Sharp and Professor Hamish McLeod facilitated access to an existing data set for 
secondary analysis. This resulted in the development of an alternative project titled 
‘Trajectories of Anxiety and Depression in Patients with Chronic Heart Failure’, which 
is featured in chapter two. The author had significant intellectual input in the direction of 
this project by completing a research protocol and contributing to the statistical analysis 
plan. See Appendix 2.2, p.159-162, for a summary of the project protocol and Appendix 
2.3, p.163, for an overview of the author’s intellectual contribution to the development 








Chapter One: Systematic Review 
 
Factors Influencing Anxiety and Depression in Implantable 






































Prepared in accordance with the author requirements for submission to the Journal of 
Clinical Nursing (Appendix 1.1, p.126).  
 
  






Aims and Objectives: To systematically review factors influencing anxiety and 
depression in implantable cardioverter defibrillator (ICD) recipients. 
 
Background: An ICD is a device used to prevent life-threatening ventricular 
arrhythmias. While the ICD is accepted by most recipients: a considerable number of 
patients experience distress following implant. The socio-demographic, clinical, ICD-
specific and psychosocial factors associated with distress in ICD-recipients has received 
increasing attention.  
 
Methods: Six electronic databases (Applied Social Science Index and Abstract, 
CINAHL, EMBASE, Medline, Psychology and Behavioral Sciences Collection and 
PsycINFO) were searched on the 24/07/2020. Additional papers were identified by hand 
searching relevant journals, forward citation searching and reviewing the reference lists 
of included studies. This review was limited to studies on adult patients who received 
a transvenous or automatic ICD or ICD with cardiac resynchronisation therapy for 
primary or secondary prevention purposes. Other inclusion criteria were peer 
reviewed quantitative papers published in English from January 2014 to July 2020, 
which examined factors influencing anxiety and depression. The quality of the papers 
was rated using the Crowe Critical Appraisal Tool.  
 
Results: Anxiety and depression were linked to socio-demographic factors (female sex, 
younger age, living alone), clinical factors (heart failure, coronary heart-disease or 
history of emotional distress/psychotropic medication use), ICD-specific factors 
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(elevated ICD-related concerns, low ICD knowledge, negative treatment expectations), 
and psychosocial factors (avoidance, perceived control, Type D personality and 
optimism).  
 
Conclusions: All papers suffered from methodological limitations and the findings 
should be interpreted with caution. Future research employing prospective longitudinal 
designs with controls for confounding factors is required to understand the relationship 
between socio-demographic, clinical, ICD-specific and psychosocial factors and distress 
in ICD-recipients over time.   
 
 
Relevance to clinical practice: Results demonstrated a relationship between elevated 
ICD-related concerns and increased distress in ICD-recipients. Routine screening for 
ICD-related concerns may identify patients at risk of anxiety and depression post ICD-
implant.  
 




















An implantable cardioverter defibrillator (ICD) is an electronic device for treating life-
threatening ventricular arrhythmias (VAs) and preventing sudden cardiac death (Magyar-
Russell et al., 2011). The ICD is implanted under the skin, and continuously monitors an 
individual's heart rhythm through electrodes. If an abnormal rhythm occurs, the ICD 
delivers electrical pulses to shock the heart to restore normal rhythms. ICDs are indicated 
for individuals at risk for VAs (primary prevention) or survivors of life-threatening VAs 
resulting in cardiac arrest (secondary prevention) (Hauer et al., 2001). 
 
Research suggests ICDs are more effective than pharmacological therapy in preventing 
sudden cardiac death (Akel & Lafferty, 2017). The ICD is accepted by most recipients; 
however, some patients experience anxiety, depression, and reduced quality of life (QoL) 
after implant (Pedersen et al., 2005). Research has reported significant inter-study 
variance in the prevalence rates of depression (24% to 33%) and anxiety (24% to 88%) 
in ICD-recipients (Camm et al., 1999). Some have suggested this variability is due to use 
of different measures to assess anxiety and depression (Magyar-Russell et al., 2011).  
 
 
A systematic review found studies using clinical interviews to assess anxiety and 
depression indicated between 11-26% of ICD participants' met criteria for an ‘anxiety or 
depressive disorder’ (Magyar-Russell et al., 2011). While rates of elevated symptoms 
(based on self-report measures) ranged from 8-63% for anxiety and 5-41% for depression 
(Magyar-Russell et al., 2011). 
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ICD-recipients with anxiety and depression are at increased risk of mortality and hospital 
re-admission (Berg et al., 2019) so an understanding the risk factors for these 
psychological responses is needed. There are several reasons hypothesised for elevated 
distress in ICD-recipients including worry about the seriousness of the heart condition 
and unpredictability of receiving device shocks (Conti & Sears, 2001). The experience 
of device shock can be distressing, and the physical sensations caused by the discharge 
can be painful and have been likened to a ‘kick in the chest’ (Ahmad et al., 2000). This 
experience can lead to a conditioned response marked by avoidance of activities 
associated with ICD shock, fuelled by anticipatory anxiety of receiving shocks (Sears & 
Conti, 2002). 
 
A body of research has investigated the demographic, clinical and psychosocial factors 
associated with increased psychological distress in ICD-recipients. One review article 
indicated socio-demographic factors including younger age (<50), female sex, and 
unemployment negatively impacted the psychological status of ICD-recipients 
(Kajanová, Bulava & Eisenberger, 2014). Two reviews reported clinical factors, 
including the number of ICD shocks received, presence of co-morbid health difficulties 
(e.g., heart failure) and time since implant are associated with anxiety and depression in 
ICD-recipients (Freedenberg, Thomas & Friedmann, 2011; Kajanová et al., 2014).  
 
Research examining the relationship between ICD-specific factors and distress including 
time since implant, receipt of device shock and ICD indication has produced mixed 
findings. Some research indicates ICD-recipients' levels of psychological distress 
reduces during the first year after implant (Amiaz et al., 2017). Others have not found 
consistent decreases over time (Van den Broek et al., 2013). Studies employing 
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prospective and longitudinal designs are required to examine the trajectories of anxiety 
and depression in ICD-recipients over time (Van den Broek et al., 2010).  
 
Similarly, the ICD shock literature is inconsistent, with only 10 out of 29 studies finding 
a significant relationship between device shock and emotional distress (Manzoni et al., 
2015). Conclusions about the relationship between device shock and distress cannot be 
drawn due to heterogeneity in the studies’ design, methodology and measures used to 
assess distress (Manzoni et al., 2015). Studies also suffer from limitations including 
collecting shock data via self-report, which is susceptible to recall bias, with 29% of ICD-
recipients underestimating and 16% overestimating the number of shocks received 
(Ahmad et al., 2000).   
 
The reason for ICD-implant may influence emotional distress, with primary prevention 
ICD-recipients reporting heightened anxiety compared to secondary prevention patients 
(Rahmawati et al., 2016). It is argued secondary prevention recipients appraise risk of 
cardiac death as higher due to previous experience and therefore view their ICDs as 
lifesaving (Rahmawati et al., 2016). Conversely, primary prevention patients have not 
experienced life-threatening cardiac event(s) and may struggle to accept why they need 
the ICD, resulting in adjustment difficulties. Data has also shown secondary ICD 
indication independently predicted depression in male ICD-recipients, while primary 
prevention indication was associated with anxiety (Miller, Thylén & Moser 2016). 
Nevertheless, findings are inconsistent as some researchers found no association between 
ICD indication and ICD-recipients' distress (Habibović, et al., 2017b; Thylén et al., 
2014).  
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The literature has also examined the relationship between psychological factors and 
emotional distress, showing Type D personality (defined as the tendency to experience 
increased negative affect while supressing these emotions due to a fear of disapproval 
from others) is associated with heightened anxiety and depression in ICD-recipients 
(Denollet & Van Heck, 2001; Kajanová et al., 2014). Additionally, research has 
supported the predictions of psychological models including the self-regulation model of 
adjustment to illness (Leventhal, Meyer & Nerenz, 1980), which highlights the role 
cognitive illness representations play in emotional adjustment. For example, one study 
found illness representations including low perceived control was independently 




ICD-specific cognitive appraisals have also been identified as influencing distress. ICD-
related concerns (e.g., worry about the ICD discharging) have been described as universal 
and are measured using the ICD Patient Concerns (ICDC) questionnaire (Pedersen et al., 
2005). Data has shown ICD-related concerns were an independent determinant of 
psychological distress after controlling for the number of shocks received (Pedersen et 
al., 2005). A multicentre study of 334 ICD-recipients found ICD-related concerns and 
low perceived control mediated the relationship between device shock and emotional 
distress (Lee et al., 2020). Accordingly, psychological factors including ICD-related 
concerns and perceptions of control may have a more substantial impact on ICD-
recipients' distress, compared to clinical factors including device shock (Lee et al., 2020; 
Pedersen et al., 2005).  
 





Given the mixed findings in previous studies, the aim of this review is to identify factors 
influencing anxiety and depression in ICD-recipients. This has the potential to help 
clinicians identify ICD-recipients at risk of less favorable outcomes and elucidate 
modifiable factors that could be targeted in the development of supportive interventions 





1.  What socio-demographic, clinical, ICD-specific and psychosocial factors influence 










Electronic Search Strategy  
 
Six electronic databases (Applied Social Science Index and Abstracts, CINAHL, 
EMBASE, Medline, Psychology and Behavioral Sciences Collection and PsycINFO) 
were searched on the 24/07/2020. Filters were used to limit search results to those 
published in journals in English. Additionally, as a previous descriptive review of factors 
influencing the psychological status of ICD-recipients was published in 2014 (Kajanová, 
Bulava & Eisenberger, 2014) a filter was used to limit search results to papers published 
from January 2014 until July 2020. All identified titles were screened for relevance and 
included or excluded according to the inclusion/exclusion criteria detailed below. 
 
Search Terms  
 
The search terms varied slightly depending on the requirements of the different databases 
use of index/subject headings and Boolean operators. See Appendix 1.2, p.127-133 for 
full details of the search strategy. The following search terms were used to search 
Psychology and Behavioral Sciences Collection (EBSCO HOST):  
1. SU (DE "ANXIETY") OR (DE "ANXIETY disorders") OR (DE 
"PSYCHOLOGICAL stress") OR (DE "DISTRESS (Psychology)") OR (DE 
"MENTAL depression") OR (DE "ADJUSTMENT disorders") OR (DE 
"AFFECTIVE disorders") OR (DE "PSYCHOLOGICAL adaptation") OR (DE 
"PSYCHOLOGICAL well-being") OR (DE "DISTRESS (Psychology)") OR 
(DE "PSYCHOLOGICAL stress") OR (DE "PATHOLOGICAL psychology") 
OR (DE "MENTAL health") 
2. TI (anxi* or depress* or mood disorder* or emotion* or psych* or (mental n2 
status) or (affective n2 disorder*) or (low n2 mood) or dysthymia or distress or 
stress or (mental n2 health) or (mental n2 illness) or (mental n2 wellbeing) or 
(mental n2 disorder*) or (psychological n2 adjustment) or (emotional n2 
adjustment) or (adjustment n2 disorder) or (emotional n2 adaptation) ) OR AB ( 
anxi* or depress* or mood disorder* or emotion* or psych* or (mental n2 
status) or (affective n2 disorder*) or (low n2 mood) or dysthymia or distress or 
stress or (mental n2 health) or (mental n2 illness) or (mental n2 wellbeing) or 
(mental n2 disorder*) or (psychological n2 adjustment) or (emotional n2 
adjustment) or (adjustment n2 disorder) or (emotional n2 adaptation) ) 
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3. S1 OR S2  
4. SU "IMPLANTABLE cardioverter-defibrillators" 
5. TI ( ( (Implantable cardioverter defibrillator or ((implantable or internal or 
automatic or automated) n2 (cardioverter or defibrillator)) or AICD or ICD). ) ) 
OR AB ( ( (Implantable cardioverter defibrillator or ((implantable or internal or 
automatic or automated) n2 (cardioverter or defibrillator)) or AICD or ICD). ) ) 
6. S4 OR S5  
7. S3 AND S6 
 
Hand searches were completed in two stages between July 2020 until October 2020. First 
the reference sections within all papers identified for inclusion were searched. Second, 
forward citation searches of included articles were conducted to identify other potentially 
relevant articles overlooked by the electronic searches.  
 
Inclusion Criteria  
• Studies written in English in peer reviewed journals.  
• Quantitative studies (randomised controlled trials (RCTs), pseudo-randomised 
trials, cohort, cross-sectional and prospective studies, case control, observational 
and descriptive studies).  
• Studies using validated questionnaires to assess anxiety and depression in ICD-
recipients (>3 months after ICD) implantation. 
• Studies including individuals ≥ 18 years with implantation of a transvenous or 
automatic ICD or ICD with cardiac resynchronization therapy (CRT-D). 
• Included individuals who received their ICD for primary or secondary prevention.  
• Included ICD-recipients with heart failure, atrial fibrillation, coronary heart 
disease, myocardial infarction, cardiomyopathy, and congenital heart conditions. 
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Exclusion Criteria  
 
• Studies published before 2014. 
• Studies where the primary aim was to validate assessment tools for anxiety or 
depression. 
• Studies only including measurements of anxiety and depression pre-ICD 
implantation or in early stages post-ICD implantation (<3 months post-implant). 
• Qualitative studies, literature reviews, book chapters, systematic reviews, 
conference abstracts, clinical guidelines, editorials or reports of expert opinions. 
• Studies investigating ICD-recipients <18 years old, those who had not yet 




The electronic search generated 6159 papers, of which 2274 were duplicates. The author 
screened the titles and abstracts of the remaining 3885 papers against the 
inclusion/exclusion criteria, of which 3835 were irrelevant. The full-text of 50 papers 
were reviewed and 31 studies were excluded. In cases where the author was unsure 
whether a paper met the inclusion criteria a second reviewer screened the paper 
independently from the author. The full-text of four papers were assessed by the second 
reviewer, and differences of opinion were resolved through discussion. Disagreements 
were minimal (i.e., the reviewers had reached the same decision to include three out of 
the four papers). One disagreement occurred, in which the second reviewer accepted one 
paper which did not meet the inclusion criteria (e.g., the paper only included a measure 
of anxiety or depression <3 months after ICD-implantation).  A total of 19 papers were 
identified for inclusion.  See Figure 1 for an overview of the selection process and 
Appendix 1.3, p.134 for details of the electronic search results.  





The data of included papers were extracted using a modified version of the Joanna Briggs 
Institute-Meta Analysis of Statistics Assessment and Review Instrument, data extraction 
tool used in a similar review (Wong, et al., 2012). See Appendix 1.4, p.135-137.  
 
 
Quality Appraisal  
The quality of the 19 papers was assessed using the Crowe Critical Appraisal Tool 
(CCAT) (Crowe, 2013). The CCAT contains eight items assessing reporting and 
methodology including: preliminaries, introduction, design, sampling, data collection, 
ethical issues, results and discussion (See Appendix 1.5, p.138-139). Each category is 
scored on a scale of zero (lowest) to five (highest) and a total score (out of 40) and 
corresponding % is obtained. For this study, a total score rating of 0-50% was judged as 
low, 51-75% moderate, and 76-100% high quality. A second researcher independently 
rated a random sample of three papers. Disagreements about ratings were minimal (all 
category scores were within 1 point), with any discrepancies being resolved through 













    
 
20 























Studies included in 
quantitative synthesis  
 (n = 19) 
Records identified through 
database searching 























n Additional records identified 
through other sources 
(n = 1) 
Records after duplicates removed 
(n = 3885) 
Records screened 
(n = 3885) 
Records excluded 
(n = 3835) 
Full-text articles assessed 
for eligibility 
(n = 50) 
Full-text articles excluded, with 
reasons 
Conference abstract only (n = 14) 
Did not examine factors 
influencing anxiety or depression 
(n = 9) 
Assessed anxiety or depression 
pre-ICD implant or within <3 
months only (n = 5) 
Included participants with a 
wearable ICD (n = 1) 
Paper published before 2014 (n = 
1) 
Non peer reviewed paper (n = 1) 
Excluded (n = 31) 
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Table 1: Overview of Studies and Summary of Findings 
Number Authors, year, 
country 
Design Participants Primary Aims Measures   Main Findings  Quality 
Rating % 

























95 ICD-recipients  
80 (84%) were 
male  


















To determine the  
prevalence of anxiety 





Recipients’ attitudes to 
ICD were collected 





morbid HF, and 
had a coronary 














shocks, but shocks 
did not correlate 
with depression 
after controlling 
for NYHA class 
and co-morbid HF 
 
53% 
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Number Authors, year, 
country 
Design Participants Primary Aims Measures  Main Findings  Quality 
Rating % 






































baseline, 142 at 3-
month and 141 at 
12-month follow-
up 
134 (85%) were 
male 


















To identify the rate of 








































D scores  
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Number Authors, year, 
country 
Design Participants Primary Aims Measures   Main Findings  Quality 
Rating % 





















88 (76.5%) were 
male  
 
Mean age: 59.85  
To investigate the 
relationship between 




BDI  Male sex, 
frequency of 
device shock, 
higher number of 
hospital 
admissions, 
family history of 
depression, were 
associated with 




4 Habibović, et 





analysis of data 
collected as part 
of the WEBCARE 
RCT (Habibović 
et al., 2017a) 
 
Measures assessed 
within 10 days 







204 (82%) were 
male  
Mean age: 58.9  
 
To investigate if 
different trajectories of 
anxiety & PTSD exist 
in ICD-recipients and 




associated with the 
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Number Authors, year, 
country 
Design Participants Primary Aims Measures   Main Findings  Quality 
Rating % 


























171 ICD-recipients  
138 (81%) were 
male  
Mean age: 59.6  
 
To explore if 
baseline optimism 
scores are related to 
ICD-recipients self-
reported depression, 














After controlling for clinical, 
demographic and personality 
characteristics: baseline optimism 
was negatively correlated with 
anxiety and depression at 12-
months 
 
Optimism was not significantly 
associated with change in 
depression and anxiety status, 
after controlling for baseline 
distress  
 
While controlling for clinical and 
demographic factors: CCI 
(comorbidities) and type D 
personality were associated with 











119 ICD-recipients  
 
86 (72.3%) were 
male 
 
Age range: 20-89 
 
To determine the 
frequency of 
avoidance 

















Avoidance behaviours were 
significantly related to depression 
with an odds ratio of 1.31. 
Subgroup analysis (excluded 
participants with CRT-D) - 
results indicated living alone and 
avoidance were associated with 
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Number Authors, year, 
country 
Design Participants Primary Aims Measures   Main Findings  Quality 
Rating % 


























analysis of data 
collected by 




990 cardiac arrest 
survivors with ICD  
Participants drawn 
from same sample as 
study 9, 14 and 15  
772 (78%) were 
male 




to match the age and 




To examine factors 
associated with HR-
QoL in cardiac arrest 
survivors who 





















Female sex, ICD-related 
concerns, being unemployed, 
type D personality, lower 
perceptions of control, co-morbid 
health-issues were correlated 
with anxiety  
 
ICD-related concerns, co-morbid 
health-issues, type D personality 
and lower perceptions of control 
were associated with depression  
58% 
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Number Authors, year, 
country 
Design Participants Primary Aims Measures   Main Findings  Quality 
Rating % 
8 Lee et al., 2020 
Australia, Korea, & 


















251 (75%) were 
male 
 
Mean age: 59  
 
To investigate if 
the correlation 
between ICD 
shocks and anxiety 
and depression 






















There was no direct effect of 
device shocks on anxiety and 
depression while controlling 
for age, ICD knowledge, and 
time since implant 
 
ICD shocks were indirectly 
associated with increased risk 
of anxiety and depression via 
the pathway of perceived 
control and ICD-related 
concerns (indirect effects on 
anxiety = 0.043, 0.060; 
indirect effects on depression 
= 0.073, 0.025) 
63% 
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Number Authors, year, 
country 
Design Participants Primary Aims Measures   Main Findings  Quality 
Rating % 
















Same sample as 
study 14 and 15  
 
Analysis included  
2771 ICD-recipients  
 
To explore the 
differences in 
anxiety, depression 
and QoL between 






















rated on a 1–4-













Low ICD knowledge, worse ICD 
experience, depression scores, 
low perceived control, low social 
support, device shock, total 
comorbidities, secondary 
prevention indication, Type D 
personality and younger age was 
associated with anxiety in males 
 
Low perceived control, type D 
personality, depression scores 
and worse ICD experience 
predicted anxiety in females  
 
Secondary ICD indication, older 
age, lower education status, 
longer time since ICD implant, 
low perceived social support, 
total comorbidities, low 
perceived control, anxiety scores, 
type D personality, and worse 
ICD experience predicted 
depression in males  
 
Poor social support, anxiety 
scores, Type D personality and 
total comorbidities predicted 
depression in females  
 
63% 
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Number Authors, year, 
country 
Design Participants Primary Aims Measures  Main Findings  Quality 
Rating % 













of data collected 
from the 
WEBCARE RCT 




assessed at baseline 
(2 weeks post ICD-





134 ICD-recipients  
111 (83%) were 
male 
















Negative treatment expectations 
(β = 0.202; p = .020) and 
baseline depression (β = 0.376; 
p < .001) emerged as 
independent predictors of 
depression at 12-month follow-
up 
While controlling for sex, 
device shocks and co-morbid 
HF, negative treatment 
expectations (β = 0.180; p = 
.043), and baseline depression 
(β = 0.353; p < .001) emerged 
as significant predictors of 
depression at 12-month follow-
up  
63% 









of data collected by 
Rahmawati et al 
(2013)  
179 ICD-recipients  
 
145 (81%) were 
male 
 
Mean age: 60.5 
 
 
To determine if 
primary prevention 
ICD-recipients are 
















After controlling for clinical 
and demographic factors 
primary prevention ICD-
recipients reported higher mean 
trait anxiety scores than 
secondary prevention recipients  
 
Primary prevention indication 
was correlated with trait anxiety 
and ICD-related concerns. 
Female sex was independently 
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Number Authors, year, 
country 
Design Participants Primary Aims Measures   Main Findings  Quality 
Rating % 














analysis of data 
collected from the 
MIDAS study, 






at baseline (1-day 
pre-implant), 10 






and their partners 
227 (79.4%) were 
male  
Mean age: 59.3 






recipients and their 
partners anxiety 






























ICD-recipients & partners 
anxiety and depression levels 
decreased over time 
 
Higher ratings of social 
support were positively 
corrected reductions in  
anxiety and depression   
 
Device shocks, secondary ICD 
indication and symptomatic 
HF was associated persistent 
anxiety  
 
Having received ≥ 1 shock 
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Number Authors, year, 
country 
Design Participants Primary Aims Measures  Main Findings  Quality 
Rating % 


















at: pre-implant, 2, 5, 
8 and 12-months 
follow-up 
 
300 ICD-recipients  
247 (82.3%) were 
male  
Mean age: 62  
 
To investigate the 
relationship between 















After controlling for (ICD 
indication, shocks, ejection 
fraction, and co-morbid health 
conditions) females reported 
higher levels of anxiety than 
males over 12-month follow-up 
 
Males and females reported 
significant reductions in anxiety 
during 12-month follow-up  
 
Depression differed across time-
points for females and males, 
with reductions seen two-months 
post-implant followed by return 








study   
 
3067 ICD-recipients  
 
2438 (79.5%) were 
male  
 







and QoL in ICD-
recipients  
 





Symptoms of anxiety and 
depression were associated with 
HF, myocardial infraction, 
younger age, and living alone. 
Female sex was associated with 
higher probability of anxiety (β = 
1.387; p = .013), elevated ICD-
related concerns was the 
strongest predictor of anxiety (β 
= 4.224; p < .001), and 
depression (β = 1.387; p < .001) 
68% 
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Number Authors, year, 
country 
Design Participants Primary Aims Measures   Main Findings  Quality 
Rating % 















Same sample as 




















related concerns were 4.98 
times more likely to 
experience anxiety compared 
to those with low concerns 
 
Having ≥ 1 shock significantly 
predicted depression and 
anxiety   
 
The relationship between 
device shock and distress was 
mediated by high levels of 
ICD-related concerns, which 
explained 54% and 68% of the 
relationship between 




16 Varghese, Geller 









423 ICD-recipients  
342 (80.9%) were 
male  








explore the link 
between PS and 








experienced PS reported 
higher anxiety scores and 
overall HADS score  
 
48% 
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Number Authors, year, 
country 
Design Participants Primary Aims Measures   Main Findings  Quality 
Rating % 












analysis of data 
collected in 
previous study 






139 ICD-recipients  
107 (77%) were 
male 
15.8% aged 50-59, 
34.5% aged 
between 60–69, 


















Being unmarried, having 
coronary heart disease, older 
age and being dependent for 
self-care was associated with 
depression. The model 
accounted for 21.6% of 
variance  
 
No clinical, demographic, 
social or ICD-related factors 
were associated with anxiety   
 
48% 







with history of 
CAD  
40 (80.7%) were 
male  




















Female sex and self-care 
dependence were significantly 
correlated with anxiety 
 
Having diabetes and self-care 
dependence were significantly 
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Number Authors, year, 
country 
Design Participants Primary Aims Measures   Main Findings  Quality 
Rating % 
















of data collected by 
(Wong et al., 2014)  
 
Same sample study 
16   
71 (ICD-only), 68 
ICD with HF 
 
To examine anxiety 
and depression and 
HR-QoL between 
ICD-recipients with 





In ICD-recipients without HF: 
older age (≥ 60) and having 
obstructive airway disease was 
positively associated with 
depression while being unmarried 
and lower education was 
negatively associated with 
depression. Presence of coronary 
heart-disease was negatively 
correlated with anxiety  
In ICD-recipients with HF: older 
age (≥ 60), and having diabetes 
was positively associated with 
depression. Self-care 
independence and higher 
education level was negatively 
associated with depression. Self-
care independence was 





Abbreviations: NYHA = New York Heart Association functional classification, HF = heart failure, PTSD = post-traumatic stress disorder, HR-QoL = health related quality of life, CRT-D = 
Cardiac Resynchronisation Therapy, CCI = Charlson Comorbidity Index, BDI = Beck Depression Inventory, Mini = Mini International Neuropsychiatric Interview, HAM-D = Hamilton 
Depression Scale, HAM-A = Hamilton Anxiety Scale, PDS = Posttraumatic-Stress Diagnostic Scale, GAD-7 = Generalised Anxiety Disorder Assessment, PHQ-9 = Patient Health 
Questionnaire, DS14 = Type D Personality Scale, LOT = Life Orientation Test, MSPSS = Multidimensional Scale of Perceived Social Support, HADS = Hospital Anxiety and Depression 
Scale, CAS = Control Attitudes Scale, SF-12 or 36 = Short-Form Health Survey 12 or 36 item, ICDC = ICD-related concerns questionnaire, MOS = Medical Outcomes Study, STAI = State-
Trait Anxiety Inventory, IES-R = Impact of Event Scale-Revisited, WAICD = The Worries About ICDs Scale modification of the 26-item Index of Subjective Concerns for People with ICDs 
(ISCP- ICD), EXPECT ICD = Expectations towards ICD therapy questionnaire, SSQ6 = Social Support Questionnaire (short version), MLHFQ = Minnesota Living with Heart Failure 
Questionnaire, EQ-5D = EuroQol-5 Dimension, EuroQol-5D-3 = EuroQol-5 Dimension 3 level. 
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Demographic and Clinical Characteristics  
 
Three papers analysed data from participants enrolled in the Webcare RCT (Habibović, et al., 
2017b; Habibović et al., 2018; Pedersen et al., 2018). Four papers used data collected from 
3067 participants recruited from the Swedish ICD and Pacemaker Registry (Israelsson et al., 
2018; Miller et al., 2016; Thylén et al., 2014; Thylén et al., 2016), and two papers used data 
collected from 139 ICD-recipients recruited by Wong et al. (2014) (Wong, 2016; Wong, 2019). 
Adjusting for these papers use of data from the same sample(s), the 19 papers included a total 
of 5521 ICD-recipients. 
 
The studies were conducted in middle to high income countries. Most papers recruited ICD-
recipients from Europe or Asia, with one multicenter study including participants from North 
America and Oceania (Lee et al., 2020). All papers specified participants’ sex, with a total of 
4395 out of 5521 (80%) being male. Age of participants ranged from 19 to 94 years. Seventeen 
papers reported average age with the mean ranging from 58.9 (Habibović, et al., 2017b) to 68 
(Varghese et al., 2019). Two papers only reported age in category ranges, with 72% and 86% 
of the samples being aged 50 and over (Inchikura et al., 2017; Wong, 2016).  
 
Fifteen papers specified participants’ ICD-implant indication, with 2321 ICD-recipients 
receiving their ICD for primary prevention and 2555 for secondary prevention. Four papers did 
not include ICD indication information, with indication unknown for 645 participants 
(Farahani et al., 2016; Lee et al., 2020; Wong 2016; Wong, 2018; Wong 2019). Eighteen papers 
included data on the experience of ICD shock, with 1693 participants reported to have had at 
least one device shock. One paper (Varghese et al., 2019) reported 27 participants experienced 
‘phantom shock’ which is the sensation of shock in the absence of an objective ICD discharge 
(Juan & Pollack, 2010).  
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Most papers reported the prevalence of distress in ICD-recipients. The prevalence of clinically 
significant symptoms of anxiety and depression (measured via self-report) ranged from 7% to 
28% for depression (Amaiz et al., 2017; Rahmawati et al., 2016) and 9% to 20.5% for anxiety 
(Habibović, et al., 2017b; Miller et al., 2016). Two papers evaluated anxiety and depression 
with the MINI ‘psychiatric interview’ and reported 2-4% met criteria for ‘new onset 
depression’, 6% met criteria for ‘dysthymia’ and 1% met criteria for anxiety (Amiaz et al., 
2016; Amaiz et al., 2017).  
 
Research Design  
 
Thirteen papers implemented a cross-sectional design. Three papers performed secondary 
analysis of data collected as part of the Webcare RCT (Habibović et al., 2017b; Habibović et 
al., 2018; Pedersen et al., 2018). Two papers utilised a longitudinal, repeated measures design 
of consecutively implanted ICD-recipients (Amiaz et al., 2017; Starrenburg et al., 2014). One 
paper (Rottmann et al., 2018) conducted secondary analysis of data collected in the MIDAS 
study, a prospective longitudinal study of consecutively implanted ICD-recipients (Pedersen et 


















    
 
36 
Methodological Quality  
 
The quality ratings of included papers using the CCAT can be found in Appendix 1.6, p.140-
141.  Fourteen papers scored between 53% and 70% indicating moderate quality. Five papers 
scored between 45% and 48%, indicating low quality and caution should be applied when 
interpreting the findings as these studies did not meet several quality assessment criteria.  
 
The main methodological limitations included: not collecting data on or statistically controlling 
for confounding variables, lack of reporting pre- or post-hoc power calculations, lack of 
information regarding attrition/missing data, and absence of reporting confidence intervals or 
effect sizes. The failure of most studies to report data on confounding variables (e.g., history 
of emotional distress, treatment with psychotropic medication or psychological therapy) means 
it is unclear whether participants experienced new difficulties or worsening of a pre-existing 
condition following ICD-implantation. Additionally, most papers implemented cross-sectional 
designs and therefore causal inferences about the relationship between demographic, clinical, 
ICD-specific and psychosocial factors and ICD-recipient’s emotional distress cannot be drawn.  
 
With regards to ethics, issues included insufficient detail on funding or conflict of interests and 













Factors influencing anxiety and depression were identified from each study. To synthesise the 
evidence, the identified factors were divided into four categories: socio-demographic, clinical 
(cardiac related and co-occurring health conditions), ICD-specific and psychosocial factors 
(See Figure 2).
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F.                                      Figure 2. Factors Hypothesised to Influence 
Anxiety and Depression 
Socio-demographic Factors 
  
• Age  
• Sex 
• Living status  
• Marital status  
• Education level  
• Occupation  
• Income level  
Clinical Factors  
 
Cardiac related  
• NYHA class  
• Heart failure   
• Myocardial infarction  
• Coronary heart disease 
• History of arrythmias  
 
Co-occurring health conditions 
• Presence or total number of 
comorbid health difficulties  
• Diabetes  
• History of depression 
• Psychotropic medication use 
 
  
ICD Specific Factors  
   
• Time since implant  
• Experience and frequency of 
device shocks  
• ICD indication (primary or 
secondary) 
• ICD-related concerns  
• Attitudes towards the ICD 
• ICD knowledge  




Psychosocial Factors  
 
• Type D personality  
• Social Support  
• Coping styles (avoidance) 
• Cognitive illness representations 
(perceived control) 
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Main Findings  
 




Ten studies reported on age as a predictive factor for anxiety and depression. Five papers 
reported no association between age and ICD-recipient's anxiety and depression scores 
(Farahani et al., 2016; Habibović et al., 2018; Israelsson et al., 2018; Rahmawati et al., 
2016; Rottmann et al., 2018). Papers with larger sample sizes, found younger age was 
associated with anxiety and depression (Habibović et al., 2017b; Thylén et al., 2014), and 
younger age was independently associated with anxiety in male ICD-recipients (Miller 
et al., 2016). Two papers found older age (>60) was associated with ICD-recipients 
depression scores, however, the quality ratings were low, limiting confidence in these 





Twelve studies reported on sex as a predictive factor for emotional distress. Five papers 
found no association between sex and ICD-recipients’ depression and anxiety scores 
(Amaiz et al., 2016; Habibović et al., 2018; Ichikura et al., 2017; Rottmann et al., 2018; 
Wong, 2016). Studies recruiting a larger number of female ICD-recipients, found females 
reported higher anxiety compared to males, after controlling for clinical confounders 
(Miller et al., 2016; Starrenburg et al., 2014). Consistent with this, three papers reported 
female sex was correlated with or emerged as an independent predictor of anxiety 
(Israelsson et al., 2018; Thylén et al., 2014; Wong 2018).  
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Rahmawati et al. (2016) found female sex was associated with depression not anxiety, 
while one paper reported male sex was associated with depression (Farahani et al., 2016). 
The quality of the Farahani et al. (2016) paper was low, therefore reducing confidence in 
this finding.  
 
Marital & Living status  
Of the five papers examining the impact of marital status on anxiety and depression, the 
studies ranged from moderate to low quality with only the low-quality papers reporting 
a link between being unmarried and higher risk of depression (Wong, 2016; Wong, 
2019). 
 
Three papers reported on living situation as a factor associated with anxiety and 
depression. Data revealed a significant relationship between living alone and higher 
anxiety and depression in ICD-recipients (Ichikura et al., 2017; Thylén et al., 2014). 
Nevertheless, one paper found cohabitation status was not associated with anxiety or 
depression (Israelsson et al., 2018).  
 
Education, income level and occupational status  
 
Six studies reported on education level as a predictor of anxiety and depression. Three 
out of four papers, which found no association between education level and participants 
anxiety and depression were of moderate quality (Farahani et al., 2016; Habibović, et al., 
2017b; Habibović, et al., 2018; Israelsson et al., 2018). Nevertheless, two papers ranging 
from low to moderate quality reported lower education status was associated with 
depression (Miller et al., 2016; Wong et al., 2019).  
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Six papers examined income level and occupational status as associating factors for 
anxiety and depression. Results revealed no significant relationship between income 
level or employment status and ICD-recipients' anxiety and depression (Amaiz et al., 
2016; Farahani et al., 2016; Habibović et al., 2017b; Ichikura et al., 2017). One paper 
found being unemployed was correlated with ICD-recipient's anxiety scores (Israelsson 




Clinical Factors  
 
Cardiac-related  
Nine papers reported on cardiac related factors including the New York Heart 
Association (NYHA) classification, presence of heart failure (HF), coronary heart 
disease (CHD), history of myocardial infarction (MI) and arrythmias.  
 
NYHA is a classification system used to describe the severity of HF symptoms based on 
how limited patients are during physical activity (Bennet et al., 2002). There are four 
classes ranging from class I (no limitation of physical activity) to class IV (unable to 
engage in physical activity without discomfort). Two papers found an association 
between higher NYHA class and increased depression scores (Amaiz et al., 2016; Amaiz 
et al., 2017). However, two studies found NYHA class did not predict change in anxiety 
or depression at 12-month follow-up (Habibović et al., 2018) or independently predict 
anxiety and depression scores (Rahmawati et al., 2016).  
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Six studies examined the relationship between history of cardiac-related disease factors 
and anxiety and depression. Two studies of moderate quality found history of HF and MI 
was associated with anxiety and depression (Thylén et al., 2014) and ‘symptomatic’ HF 
was associated with persistent anxiety at 12-months (Rottmann et al., 2018). One paper 
of moderate quality found no association between baseline HF diagnosis and trajectories 
of anxiety over 12-months (Habibović et al., 2017b). Wong (2016) also found no 
association between history of HF or history of arrhythmias and ICD-recipients’ anxiety 
and depression. The quality of this paper was low, limiting confidence in these findings.   
 
Additionally, two low quality papers reported an association between CHD and anxiety 
and depression in ICD-recipients (Wong, 2016; Wong 2019). Consistent with this, Amaiz 
et al. (2016) found participants who had undergone a coronary artery bypass graft (a 
surgical procedure for CHD) reported increased depression. Nevertheless, higher quality 
evidence is needed before a firm conclusion about the relationship between CHD and 
risk of distress in ICD-recipients can be drawn.  
 
Co-occurring health conditions  
 
Seven papers reported on the relationship between co-occurring health issues and ICD-
recipients' symptoms of anxiety and depression. The results were inconsistent with one 
study finding no association between Charlson Comorbidity Index (CCI) and ICD-
recipients' trajectories of anxiety during 12-month follow-up (Habibović et al., 2017b). 
However, Habibović et al. (2018) reported higher medical co-morbidity (measured using 
the CCI) was associated with increased anxiety and depression. Similarly, the presence 
of comorbidities was correlated with ICD-recipient’s anxiety and depression scores 
(Israelsson et al., 2018). Moreover, Miller et al. (2016) reported the total number of 
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comorbidities were associated with increased anxiety and depression in male ICD-
recipients.  
 
Three papers explored the relationship between diabetes and ICD-recipients' distress 
(Amaiz et al., 2016; Wong, 2018; Wong 2019). Of the three papers examining the 
relationship between diabetes and emotional distress, the studies ranged from moderate 
to low quality with only the low-quality papers finding a link between diabetes and 
increased depression (Wong, 2018; Wong 2019).  
 
Depression History  
 
Two papers reported personal/family history of emotional distress as a predictive factor 
for depression. One moderate quality paper found ICD-recipients with a history of mental 
health difficulties and psychotropic medication use reported higher depression scores 
during 12-month follow-up (Amaiz et al., 2017). Furthermore, a low-quality paper found 
an independent association between family history of depression and ICD-recipients 
depression scores (Farahani et al., 2016).  
 
 
ICD-specific factors  
 
ICD indication  
 
Six studies reported on ICD indication (primary vs secondary prevention) as a predictive 
factor for anxiety and depression. Overall, the findings were variable, with three studies 
finding no association between ICD indication and anxiety or depression (Habibović et 
al., 2017b; Habibović et al., 2018; Thylén et al., 2014). Conversely, secondary ICD 
indication emerged as an independent predictor of anxiety and depression in male ICD-
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recipients (Miller et al., 2016). Similarly, data from Rottmann et al. (2018) revealed 
secondary ICD indication was associated with persistent anxiety during 12-month 
follow-up. Rahmawati et al. (2016) found the opposite trend with primary indication 
being associated with ICD-recipient's trait anxiety scores. 
 
 
Time since implant  
 
Nine papers examined the relationship between time since implant and ICD-recipients' 
emotional distress. Five papers implementing a cross-sectional design found no 
association between time since implant and ICD-recipients' anxiety or depression scores 
(Amaiz et al., 2016; Farahani et al., 2016; Israelesson et al., 2018; Thylén et al., 2014; 
Wong, 2016). Nevertheless, one cross-sectional study reported longer time since implant 
was associated with higher depression levels in male ICD-recipients (Miller et al., 2016).  
 
Overall, studies implementing longitudinal designs found significant decreases in ICD-
recipients' anxiety and depression scores between baseline and 12-month follow-up 
(Amaiz et al., 2017; Rottmann et al., 2018; Starrenburg et at., 2014). However, 
Starrenburg et al. (2014) reported a trend in which depression scores reduced at two 
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Device Shocks  
Fourteen papers reported on the experience of device shock as a predictive factor for 
anxiety and depression. Data was inconsistent, with seven studies reporting no 
association between experience/frequency of device shocks and ICD-recipients distress 
(Amaiz et al., 2017; Habibovic et al., 2017b; Ichikura et al., 2017; Israelesson et al 2018; 
Rahmawati et al., 2016; Thylén et al., 2014; Wong 2016).  
 
Conversely, two papers of moderate quality, found device shock independently predicted 
anxiety in male ICD-recipients (Miller et al., 2016) and was associated with persistent 
anxiety during 12-month follow-up (Rottmann et al., 2018). Data also showed a 
significant relationship between device shock and ICD-recipients’ depression scores 
(Farahani et al., 2016) and ‘phantom shocks’ were associated with increased anxiety 
(Varghese et al., 2019). Nevertheless, the quality of these papers was low, limiting the 
confidence in these findings.  
 
Moderate quality papers found device shocks were no longer associated with depression 
in ICD-recipients after controlling for NYHA class and HF diagnosis (Amaiz et al., 
2016). Similarly, there was no direct effect of device shock on ICD-recipients' anxiety 
and depression after controlling for ICD-related concerns, ICD knowledge and time since 
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ICD-related concerns  
Four moderate quality papers explored the influence of ICD-related concerns on 
emotional distress. The findings were consistent with all four papers finding a significant 
association between elevated ICD-related concerns and increased anxiety and depression 
(Israelsson et al., 2018; Lee et al., 2020; Thylén et al., 2014; Thylén et al., 2016). 
Moreover, elevated ICD-related concerns emerged as the strongest predictor of 
probability of anxiety and depression symptoms, with odds ratios of 4.224 and 2.919 
respectively (Thylén et al., 2014). Additionally, data indicated elevated ICD-related 
concerns statistically mediated the relationship between device shock and anxiety and 
depression (Lee et al., 2020; Thylén., 2016).  
 
 
Attitudes/ knowledge of the ICD  
 
Three studies with moderate quality ratings, explored the relationship between other 
ICD-related factors and emotional distress. One paper found ICD-recipients’ attitudes 
towards their device were positively associated with depression (Amaiz et al., 2016). 
Results also revealed perceptions of worse ICD experience, low ICD knowledge and 
negative treatment expectations were associated with anxiety or depression (Miller et al., 
2016; Pedersen et al., 2018). However, Pedersen et al. (2018) noted negative treatment 
expectations were weakly associated with depression at 12-months after controlling for 











Five papers reported on personality type as a predictive factor for distress. Overall, four 
papers, with moderate quality ratings found Type D personality was associated with ICD-
recipients’ anxiety and depression scores during follow-up (Habibović, et al., 2017b; 
Habibović, et al., 2018; Israelsson et al., 2018; Miller et al., 2016). Nevertheless, Type D 
personality did not independently predict anxiety and depression after controlling for sex, 
device shocks and comorbid HF (Pedersen et al., 2018).  
 
Social Support  
Two moderate quality papers reported on perceived social support as a predictive factor 
for anxiety and depression. One paper examining sex differences, found perceptions of 
social support predicted depression in male and female ICD-recipients (Miller et al., 
2016). Rottmann et al. (2018) also found higher ratings of social support were associated 
with reduced anxiety and depression during 12-month follow-up.  
 
Coping Styles  
One paper reported on coping styles including avoidance behaviours as a factor related 
to depression in ICD-recipients. Data indicated avoidance behaviours (e.g., avoidance of 
activity or places) were associated with heightened odds of depressive symptoms 
(Ichikura et al., 2017). The quality of this paper was moderate, however, the cause-and-
effect relationship between avoidance and depression is unclear due to the 
implementation of a cross-sectional design.  
 
 




Three papers with moderate quality ratings reported on the relationship between illness 
representations and emotional distress. Results showed significant associations between 
low perceptions of control and higher anxiety and depression scores in ICD-recipients 




One moderate quality paper reported on positive psychological constructs as a predictive 
factor for anxiety and depression. Results showed baseline optimism was negatively 
associated with ICD-recipient's anxiety and depression at 12-month follow-up, after 
controlling for clinical, demographic and personality variables (Habibović et al., 2018). 
Baseline optimism was no longer associated with change in anxiety and depression after 
controlling for baseline distress. The paper also suffered from limitations including 
















The aim of this review was to systematically review the factors influencing anxiety and 
depression in ICD-recipients. A summary of the main findings will be presented in the 
context of the reviewed papers methodological quality. Similar to a previous systematic 
review investigating distress in ICD-recipients (Magyar et al., 2011) the reviewed studies 
reported a large range in the prevalence of self-reported clinically significant symptoms 
of anxiety (9% to 25%) and depression (7% to 28%). The variation in prevalence rates 
may be explained by inter-study differences in time between ICD-implant and study 
commencement, study design, and differences in measures or clinical threshold criteria 
employed.  
 
Socio-demographic factors  
There is moderate quality evidence to suggest that younger age is associated with 
increased anxiety and depression in ICD-recipients (Habibović et al., 2017b; Miller et 
al., 2016; Thylén et al., 2014). This finding is consistent with a previous review reporting 
younger age (<50) was associated with poorer adjustment in ICD-recipients (Kajanová 
et al., 2014).  
 
Results provided tentative evidence that female sex was associated with increased 
anxiety in ICD-recipients (Israelsson et al., 2018; Miller et al., 2016; Starrenburg et al., 
2014; Thylén et al., 2014). These findings are consistent with a review which reported 
greater anxiety among female ICD-recipients (Freedenberg et al., 2011). Nevertheless, 
this result may reflect the well-documented finding, that the prevalence rate for anxiety 
in the general population is higher in females (Kessler et al., 1994). Additionally, some 
studies found no relationship between female sex and anxiety (Amaiz et al., 2016; 
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Habibović et al., 2018; Ichikura et al., 2017; Rottmann et al., 2018; Wong, 2016). 
However, these findings should be interpreted with caution as the papers did not report 
power calculations and recruited a small sample of female ICD-recipients (N < 60). 
Consequently, these papers may not have been adequately powered to identify sex 
differences.  
 
Overall, evidence indicated no significant association between marital status, education 
level income level or employment status and anxiety and depression ICD-recipients 
(Amaiz et al., 2016; Farahani et al., 2016; Habibović et al., 2017b; Habibović et al., 2018; 
Ichikura et al., 2017; Israelsson et al., 2018). There was some moderate quality evidence 
to suggest a significant relationship between living alone and increased risk of distress in 
ICD-recipients (Ichikura et al., 2017; Thylén et al., 2014).  
 
 
Clinical factors  
 
Results provided tentative evidence that higher NYHA class, HF or CHD were associated 
with increased anxiety and or depression in ICD-recipients (Amaiz et al., 2016; Amaiz 
et al., 2017; Rottmann et al., 2018; Thylén et al., 2014; Wong 2016; Wong, 2019). These 
findings support, previous research reporting a significant relationship between 
symptomatic HF and distress in ICD-recipients (Freedenberg et al., 2011). Nevertheless, 
some papers found no relationship between NYHA class and history of HF and emotional 
distress (Habibović et al., 2017b; Habibović et al., 2018; Rahmawati et al., 2016; Wong, 
2016). The mixed results may be partially explained by inter-study variance in the clinical 
characteristics of participants. The papers finding no association between NYHA class 
or HF diagnosis and distress recruited a higher proportion of ICD-recipients within 
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NYHA classification I and II, suggesting milder severity of HF (Habibović et al., 2018; 
Rahmawati et al., 2016).  
 
 
Results provided preliminary evidence that the presence of or total number of co-
morbidities are associated with anxiety and depression in ICD-recipients (Habibović et 
al., 2018; Israelson et al., 2018; Miller et al., 2016; Wong, 2018). Nevertheless, one paper 
found no association between Charlson Comorbidity Index and ICD-recipients’ 
trajectories of anxiety at 12-months (Habibović et al., 2017b). There was significant 
variance in how data on co-occurring conditions were measured including self-report 
(Israelsson et al., 2018), review of medical notes (Amaiz et al., 2016) or a validated tool 
(the CCI) (e.g., Habibović et al., 2017b). Future research using a standardised approach 
to measuring comorbidities, that avoids methods prone to recall bias (i.e., self-report) are 
required to fully understand the influence comorbidities have on ICD-recipients’ 
emotional distress over time. 
 
There was low to moderate quality evidence to suggest ICD-recipients with a personal 
or family history of mental health difficulties, and psychotropic medication use were at 
greater risk of depression (Amaiz et al., 2017; Farhani et al., 2016). Future research is 
required to identify if these factors are associated with increased risk of anxiety in ICD-
recipients.  
 
ICD-specific factors  
 
Collectively results showed the relationship between device shock and distress is not 
straightforward. Evidence was inconsistent with seven out of fourteen papers finding no 
association between device shock and ICD-recipients’ anxiety and depression. This 
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finding is similar to results of a systematic review reporting only 10 out of 29 studies 
found a relationship between device shock and distress (Manzoni et al., 2015).  
 
There was preliminary evidence to suggest device shock does not have a direct effect on 
ICD-recipients’ distress. Device shock had no effect on ICD-recipient’s anxiety and 
depression after controlling for NYHA class and ICD-related concerns (Amaiz et al., 
2016; Thylén et al., 2016). Instead, evidence suggested the relationship between shock 
and emotional distress was statistically mediated by elevated ICD-related concerns and 
perceptions of control (Lee et al., 2020; Thylén et al., 2016).  
 
There was heterogeneity in how data on ICD shock experience was collected, with 
several papers collecting data via self-report (Lee et al., 2020; Thylén et al., 2016) while 
other studies gathered objective data from device interrogation (Rottmann et al., 2018). 
It is possible the studies collecting shock data via self-report were prone to recall bias, 
which may affect the findings. Data has shown, 29% of ICD-recipients underestimated 
the number of shocks received, and longer duration of implant was associated with 
increased inaccuracy (Ahmad et al., 2000).  
 
Longitudinal studies found reductions in ICD-recipients’ anxiety or depression scores 
between baseline (pre-implant) and 12-month follow-up (Amaiz et al., 2017; Rottmann 
et al., 2018; Starrenburg et at., 2014). However, the cross-sectional studies found no 
relationship between time since implant and ICD-recipients anxiety and depression 
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These findings suggest the choice of research design can influence whether an effect of 
time on ICD-recipients distress is detected. For cross-sectional studies, there was inter-
study variance in the time elapsed between ICD-implant and study commencement, 
making it difficult to make comparisons between studies. The longitudinal studies 
investigating the impact of time also had limitations. Two papers did not collect data on 
confounding factors including history of distress or treatment with medication or therapy 
(Rottmann et al., 2018; Starrenburg et at., 2014). Accordingly, further studies using 
prospective and longitudinal designs, with controls for confounding factors are required 
to accurately describe the trajectories of anxiety and depression in ICD-recipients over 
time.  
 
There is moderate quality evidence to suggest a significant relationship between ICD-
related concerns and ICD-recipients’ anxiety and depression (Israelsson et al., 2018; Lee 
et al., 2020; Thylén et al., 2014; Thylén et al., 2016). Data also showed elevated ICD 
related concerns mediated the relationship between device shock and emotional distress 
(Lee et al., 2020; Thylén et al., 2016). These findings are consistent with earlier research 
which reported ICD-related concerns emerged as an independent determinant of distress 
after controlling for number of device shocks received (Pedersen et al., 2005).  
 
Nevertheless, the results should be interpreted with caution due to studies use of cross-
sectional designs, which means no conclusions about the causal relationship between 
ICD-related concerns, device shock and distress can be drawn. Future research using 
prospective longitudinal designs is required to replicate the findings and further elucidate 
the relationship between anxiety, depression, ICD-related concerns and device shock.  
 




Evidence also revealed a significant independent association between ICD-specific 
factors including perceptions of worse ICD experience, low ICD knowledge and negative 
treatment expectations and anxiety or depression (Miller et al., 2016; Pedersen et al., 
2018). This finding supports previous research indicating inappropriate patient 
education/knowledge was associated with distress in ICD-recipients (Kajanová et al., 
2014).  
 
Psychosocial factors  
 
Evidence suggested psychosocial factors including coping styles (avoidance) and 
cognitive illness representations (low perceptions of control) were associated with 
increased anxiety and or depression in ICD-recipients (Ichikura et al., 2017; Israelsson 
et al., 2018; Lee et al., 2020; Miller et al., 2020). These findings are consistent with the 
self-regulation model (Leventhal et al.,1980) which highlights the role cognitive illness 
representations play in the emotional adjustment to health conditions. Nevertheless, these 
findings should be interpreted with caution as these papers suffered methodological 
limitations. The papers did not adequately control for extraneous factors (e.g., history of 
anxiety or depression or psychotropic medication use) and implemented cross-sectional 
designs, which precludes conclusions about causality.  Accordingly, subsequent 
longitudinal studies controlling for confounding variables are required to identify 
whether perceptions of control and avoidance behaviours predict emotional adjustment 




There was tentative evidence to suggest lower perceptions of social support was 
associated with depression (Miller et al., 2016) and high ratings associated with 
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improvement in anxiety and depression in ICD-recipients (Rottmann et al., 2018). 
Nevertheless, the papers acknowledged methodological limitations including not 
collecting data on actual social support received post ICD-implantation. Perceptions of 
social support can be viewed as an index of intrapersonal processes, shaped by relational 
schemas as opposed to providing a measure of actual environmental supports (Uchino, 
2009). Consequently, future studies could examine the influence that actual received 
support and perceptions of social support have on the emotional adjustment of ICD-
recipients to elucidate targets for intervention.  
 
 
Overall, data suggested Type D personality was associated with increased anxiety and 
depression in ICD-recipients (Habibović, et al., 2017b; Habibović, et al., 2018; Israelsson 
et al., 2018; Miller et al., 2016). This finding is consistent with a previous review 
indicating Type D personality is linked to distress in ICD-recipients (Kajanová et al., 
2014). Nevertheless, Type D personality did not predict distress after controlling for 
device shock, sex and co-occurring HF (Pedersen et al., 2018).  
 
Further research, controlling for confounding factors is required to identify whether Type 
D personality is an independent predictor of distress in ICD-recipients or overlaps with 
other constructs. There has been debate in the literature about the validity and utility of 
the Type D personality construct because the increased negative affectivity component 
(central to the construct) overlaps with symptoms of depression (Stepto & Molloy, 2007).  
 
 
Finally, there was preliminary evidence to suggest after controlling for demographic, 
clinical and personality variables, baseline optimism was associated with reduced anxiety 
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and depression in ICD-recipients (Habibović, et al., 2018). This finding should be 
interpreted with caution as the study had limitations including a significant number of 
participants being excluded from the analysis. Consequently, the sample could be biased 
towards ICD-recipients who are motivated to participate or experience less severe health 
impacts, which may affect the generalisability of the findings.  
 
 
Methodological Limitations  
 
The current review suffered from methodological limitations and the results should be 
interpreted with caution. First, 80% of ICD-recipients in included studies were male. This 
reflects the ICD population with females not receiving ICD implants at the same rates as 
their male counterparts (McSweeney et al., 2012). It therefore remains unclear if the 
findings can be generalised to female ICD-recipients.  
 
Second, most studies did not collect data on ICD-recipients’ history of distress. It is 
therefore unknown if participants anxiety and depression symptoms existed prior to ICD-
implantation or developed in response to implantation. 
 
Third, included papers were conducted in middle-to-high income countries and most 
studies took place in Europe or Asia. There are documented differences between high 
income and developing countries in terms of access to ICD treatment (Sani & Mayosi, 
2017). Therefore, it will be useful to include research from developing countries to 
increase the cultural validity and generalisability of the findings.  
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Most papers relied on self-report measures of emotional distress, while only two papers 
supplemented data with ‘diagnostic interviews’ (Amaiz et al., 2016; Amaiz et al., 2017). 
The use of self-report measures of distress is subject to sources of bias including social-
desirability bias and regression to the mean, which may impact the findings.  
 
Additionally, only two of the included studies reported a power calculation (Farhani et 
al., 2016; Ichikura et al., 2017) to justify the recruited sample size. Consequently, 
precluding the risk of occurrence of type II error in the other studies is challenging 
because it is unclear whether studies were adequately powered to investigate the 
relationship between multiple variables. Nevertheless, findings, particularly in relation 
to psychosocial variables and ICD-related factors were replicated across studies, giving 
a provisional indication this risk was not high.  
 
Conclusion 
Overall, this review identified socio-demographic factors (female sex, younger age, 
living alone), clinical factors (HF, history of CHD or emotional distress), ICD-specific 
factors (elevated ICD-related concerns, low ICD knowledge, negative treatment 
expectations), and psychosocial factors (avoidance behaviours, low perceived control, 
and Type D personality) may worsen anxiety and depression in ICD-recipients. But the 
generally poor methodological quality of papers suggests these results should be treated 
cautiously. Future research that is: adequately powered, employs prospective 
longitudinal designs and controls for confounding factors is required to fully understand 
the relationship between sociodemographic, clinical, ICD-specific and psychosocial 
factors and distress in ICD-recipients over time.   
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Relevance to Clinical Practice  
 
The findings from this review support earlier research (Pedersen et al., 2005) 
demonstrating a relationship between elevated ICD-related concerns and emotional 
distress. Accordingly, routine screening for ICD-related concerns using the validated 
ICDC questionnaire may help identify patients at risk of developing anxiety and 
depression post ICD-implant.  
 
The results provide preliminary evidence to suggest ICD-recipients with symptomatic 
HF or CHD, female ICD-recipients, those with Type D personality, younger ICD-
recipients (<50), and those with a history of distress or previous treatment with 
psychotropic medication may be at increased risk of distress. Therefore, these 
characteristics may be useful in identifying those at risk for distress after implant.  
 
Results also provide initial evidence to suggest knowledge of the ICD, coping styles 
(avoidance), cognitive appraisals (ICD-related concerns, treatment expectations and 
perceptions of control) influence anxiety and depression in ICD-recipients. These factors 
are modifiable and may represent useful factors to target during educational or 
psychosocial interventions. Results also suggest perceptions of social support are 
associated with emotional outcomes in ICD-recipients. Therefore, relational 
interventions aimed at improving ICD-recipients’ access to social support or ability to 
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Plain Language Summary 
  
Background: Research suggests people with chronic heart failure (CHF) report 
increased rates of anxiety and depression compared to the general population. CHF 
patients with anxiety and depression are at increased risk of poorer outcomes including 
hospital readmission. There has been little research looking at how anxiety and 
depression develops over time in people with CHF. It is important to explore how anxiety 
and depression develops to find out whether anxiety or depression symptoms are short-
lived or persistent.   
  
Aim: To describe how symptoms of anxiety and depression develop over 12-months in 
a sample of people with CHF.   
  
Methods: The project involved analysing data collected from a previous study which 
looked at the palliative care needs of CHF patients (Campbell et al., 2018). Data were 
analysed using statistical tests. Ethical approval for this project was granted by NHS 
Greater Glasgow and Clyde’s Research and Innovation department.   
  
Results: Overall, the proportion of the sample reporting anxiety and depression 
symptoms was higher during a period of hospital admission and reduced significantly by 
12-months. Data also indicated the majority of the sample did not report anxiety or 
depression or experienced resolution in their symptoms at 4, 8 and 12-month follow-up. 
Nevertheless, results showed 21% of the sample who reported symptoms of anxiety and 
depression during hospital admission experienced persistent symptoms at 12-month 
follow-up. Furthermore, a small percentage of patients who were anxiety or depression 
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symptom free during hospital admission went on to develop anxiety or depression by 12-
months.    
  
Conclusions and implications: Although the majority of people with CHF in this 
sample experienced no or relatively short-lived symptoms of anxiety and depression, 
some experienced persistent symptoms. Routine and repeated screening for anxiety and 
depression in outpatient settings or primary care is recommended for this population.  
  
References: Campbell, R. T., Petrie, M. C., Jackson, C. E., Jhund, P. S., Wright, A., 
Gardner, R. S., ... & McMurray, J. J. (2018). Which patients with heart failure should 
receive specialist palliative care? European journal of heart failure, 20(9), 1338-1347.  
  





Aims and Objectives:  To describe the trajectory of anxiety and depression in Chronic 
Heart Failure (CHF) patients during 12-month follow-up and to identify characteristics 
independently associated with anxiety and depression.  
 
Background: CHF patients with depression and anxiety are at increased risk 
of poorer outcomes including hospital readmission. There is limited research describing 
the trajectories of anxiety and depression in CHF patients over time.  
 
Design: The study was a secondary analysis of data collected in a longitudinal study 
investigating the palliative care needs of 272 CHF patients in Glasgow.  
 
Methods: Anxiety and depression were assessed using the Hospital Anxiety and 
Depression Scale (HADS) at baseline and every four-months.  
 
Results: From baseline to 12-months, there was a significant reduction in the proportion 
of CHF patients reporting symptoms of anxiety (43.5% vs 25%) and depression (40% vs 
27.4%). Looking at change in HADS scores over 12-months, 54.3% of patients were free 
of significant anxiety at all assessments, 21.7% showed an improvement in initially 
distressing anxiety, and 2.2% developed anxiety as the study progressed. Based on 
change in HADS depression scores across 12-months, 53.7% did not report significant 
depression, 18.9% experienced resolution of depression symptoms, and 6.3% went on to 
develop depression as the study progressed. One in five patients experienced persistent 
anxiety and depression throughout. In regression analysis, baseline anxiety, health-
related quality of life, history of depression and female sex emerged as predictors of 
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anxiety, while baseline depression, history of depression, antidepressant medication use, 
and female sex predicted depression.  
 
Conclusions: Results suggest a significant reduction in the proportion of CHF patients 
reporting clinically significant anxiety and depression from baseline to 12-month follow-
up. Although there was a subset of participants that experienced persistent symptoms  
of anxiety and depression.  
 
Relevance to Clinical Practice: Routine screening for anxiety and depression in CHF 
patients is recommended.   
 
Keywords: anxiety, depression, heart failure.   





Chronic Heart failure (CHF) is associated with poor prognosis in terms of mortality and 
on-going symptom burden (Soriano et al., 2010).  The disease course 
of CHF is characterised by phases of stability, punctuated by periods of acute worsening 
of symptoms, with these exacerbations often being unexpected and life 
threatening (Goodlin, 2009).  
 
Accordingly, psychological adjustment to CHF is challenging.  The prevalence 
of depression is about one in five, with estimates influenced by the use of diagnostic 
interview versus self-report methods (19.3% and 33.6% respectively) (Rutledge, Reis, 
Linke, Greenberg & Mills, 2006). Additionally, a systematic review and meta-analysis 
reported a pool prevalence of 13.1% for ‘anxiety disorders’ in people with CHF, and 30% 
self-reported clinically significant anxiety symptoms (Easton, Coventry, Lovell, Carter 
& Deaton, 2016). This is higher than the point prevalence estimates for the general 
population of 12.9% for depression and 7.2% for anxiety (Lim et al., 2018; Martín-
Merino, Ruigómez, Wallander, Johansson & García-Rodríguez, 2010). 
 
CHF patients who experience anxiety and depression have poorer outcomes compared to 
their non-distressed counterparts. Evidence suggests depression is associated with 
increased risk of both death and hospital readmission plus poorer health-related quality 
of life (HR-QoL) (Dekker et al., 2011; Rutledge et al., 2006). Anxiety has been linked to 
HF-related hospital readmission and poorer functioning (Shen et al., 2011; Tsuchihashi-
Makaya, Kato, Chishaki, Takeshita & Tsutsui, 2009).   
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Psychological theory can be applied to understand emotional adjustment to CHF. The 
working model of adjustment asserts critical events (development of initial symptoms of 
illness, diagnosis, and disease progression) initially disrupts an individual’s ‘emotional 
equilibrium’ leading to distress (Moss-Morris, 2013). In accordance with this, data 
indicates the development of depression is associated with periods of acute worsening 
of CHF symptoms (Johansson et al., 2013), and people hospitalised with CHF report 
higher rates of depression compared to outpatients experiencing stability in their 
symptoms (Konstam, Moser & De Jong, 2005).  
 
The working model of adjustment also proposes background factors (e.g., social support, 
age, previous life experiences), on-going illness-specific factors (e.g., the nature of 
symptoms, degree of uncertainty) and cognitive-behavioural factors (e.g., negative 
illness representations, avoidant coping) can lead to on-going emotional 
disequilibrium/adjustment difficulties (Moss-Morris, 2013). Research in CHF 
populations appears to support these predictions. Depression in CHF patients is 
associated with demographic factors (female sex), social factors (quality of social 
support), clinical factors (functional severity of CHF as measured by New York Heart 
Association Functional Classification – NYHA class), and psychological factors (coping 
styles, low perceptions of control) (Haworth et al., 2005; Lerdal, Hofoss, Gay & 
Fagermoen, 2019; Tsuchihashi-Makaya et al., 2009).   
 
Comparatively fewer studies have examined predictors of anxiety in CHF patients and 
most research is cross-sectional. From these studies, increased somatic symptoms, 
smoking and drinking status, reduced HR-QoL and history of depression have all been 
associated with anxiety in cardiac populations (Allabadi et al., 2019; Årestedt et al., 
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2014).  Additionally, presence of depression and younger age independently predicted 
anxiety in sample of outpatients with CHF, while ethnicity, and NYHA class did not 
(Årestedt et al., 2014).  
 
 
Trajectories Over Time  
There has been limited research investigating the longitudinal trajectories of depression 
and anxiety in CHF patients (Decker et al., 2011; Johansson et al., 2013; Koenig, 
Vandermeer, Chambers, Burr-Crutchfield & Johnson, 2006). A study of 256 CHF 
patients in the US found 15% experienced resolution of ‘depressive symptoms’ after 3-6 
months (Dekker et al., 2011), while a separate study reported 61% had recovered by 18 
months (Johansson et al., 2013).  
 
However, not all patients follow an improvement trajectory. Across studies, of the CHF 
patients who reported clinically significant depression at baseline: at 6 weeks follow-up 
27.3% experienced persistent symptoms (Koenig et al., 2006), at 3-6 months 15% 
experienced persistent depression (Dekker et al., 2011), and at 18-month follow-up and 
39% reported persistent depression (Johansson et al., 2013). Additionally, data showed 
6% of CHF patients sampled developed clinically significant depression at 3–6-month 
follow-up (Dekker et al., 2011), and 18% developed depression after 18-months 
(Johansson et al., 2013).  
 
Patient characteristics including co-occurring health problems, history of emotional 
distress and psychotropic medication use may predict whether CHF patients follow a 
‘depression not improved’ trajectory at follow-up (Koenig et al., 2006).  The 
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development of depression at follow-up has also been associated with behavioural factors 
(excess alcohol use), socio-demographic factors (living alone) and baseline disease 
specific HR-QoL (as measured by the Kansas City Cardiomyopathy Questionnaire 
- KCCQ) (Havranek, Spertus, Masoudi, Johnes & Rumsfeld, 2004). Surprisingly, 
depression at follow-up was not associated with indicators of disease severity (NYHA 
class, ejection fraction %) or commonly identified risk factors for depression in the 
general population including age (Havranek et al., 2004).  
 
 
Justification for the Proposed Study   
 
Very few studies examine the trajectories of anxiety in individuals with CHF. Most 
research is limited by a focus on depression (Volz et al., 2011) and so it is unclear how 
anxiety symptoms in people with CHF develops over time. The demographic, clinical or 
psychosocial predictors of anxiety and depression across time in people with CHF also 
warrant attention.  
  
It is important to explore how anxiety and depression in CHF patients develops 
to identify whether anxiety and depression are transient or whether difficulties follow a 
more persistent course. Such information may help to inform 
clinician’s about when to screen for anxiety and depression symptoms (Johansson et al., 
2013). Additionally, identifying the demographic and clinical characteristics associated 
with anxiety and depression is important to help clinicians to identify CHF patients at 









The primary aim of this study was to describe the trajectories of anxiety and depression 
in a sample of patients with CHF over 12-month follow-up. The secondary aim was 
to identify baseline demographic and clinical factors that are independently associated 
with anxiety and depression.  
 
Based on previous research and on the predictions of Moss-Morris’s (2013) working 
model of psychological adjustment it was hypothesised that: 
• Levels of anxiety and depression in CHF patients would decrease from baseline 
(index admission) to 12-month follow-up.  
•  Anxiety and depressive symptoms would be associated with relevant background 
factors (e.g., sex, age, history of depression and or anti-depressant use). 
• Anxiety and depressive symptoms would be associated with illness-specific 
factors (e.g., level of symptom burden, disease-specific HR-QoL).  
• Anxiety and depressive symptoms would be associated with behavioural factors 














The study was a secondary analysis of longitudinal data which had investigated palliative 
care needs of people with CHF (Campbell et al., 2018). The design and rationale of the 
original study has been published elsewhere (Campbell et al., 2015) and included a near 
consecutively recruited sample of 272 CHF patients who were admitted to hospital and 
followed up for up to 28-months. 120 (44.1%) of participants had been diagnosed with 
CHF prior to the index admission and 152 (55.9%) were diagnosed during admission. 
Eligible participants were aged 18 years and over and met the following inclusion criteria 
(See table 2).  
 
Table 2 Inclusion and Exclusion Criteria  
 
Inclusion Criteria  Exclusion Criteria  
• Admitted to the Western Infirmary 
hospital in Glasgow (between 9th 
January 2013 to 1st December 2014) 
with a primary diagnosis of acute 
decompensated HF 
 
• Had a BNP level <100 pg/mL 
 
• Lack of capacity to provide informed 
consent (presented with dementia, 
learning difficulties, were moribund or 
unable to read/write in English) 
 
• Fulfilled the European Society of 
Cardiology (ESC) echocardiographic 
diagnostic criteria for guidelines for 
the diagnosis of HF  
• Were re-admitted after the index 
admission (baseline)  
 
• Presented with acute coronary 
syndrome complicated by pulmonary 
oedema or isolated cor pulmonale  
 
• Had B-type natriuretic peptide (BNP) 
level > 100 pg/mL 
 
 
• Participants with valvular HF, HF 
with reduced ejection fraction, and HF 










Ethical approval for Campbell and colleagues (2018) study was granted by the West of 
Scotland Research Ethics committee (REC Ref: 12/WS/0224; IRAS Ref 100839). All 
enrolled participants consented to ‘passive follow-up' through medical record linkage, 
accessed through the Greater Glasgow and Clyde SafeHaven service. Participants 
provided consent for their anonymised data being analysed in future research. For the 
present study, Research and Innovation Management (R&I) approval was obtained from 
Greater Glasgow & Clyde (See appendix 2.4, p.164-165).  
 
Protocol  
Participant's symptom burden, anxiety, depression and HR-QoL (using the patient 
reported outcome measures detailed below) were assessed during the index admission 
(baseline), and then at 4-monthly intervals for up to 28-months. Measures were 
completed during study visits, which took place in the Western Infirmary or in 
participants own homes, if they were too unwell to travel.  
 
Measures  
Demographic, Clinical and Behavioural Data  
 
Baseline demographic, clinical and behavioural characteristics were collected during 
participants index admission via medial note review and patient interview (Campbell et 
al., 2015). Demographic information included age (in years), sex (female, male) and 
ethnicity (Arab/Middle East, Black, South Asian, White). Clinical information included 
ejection fraction (< 50%, > = 50%), NYHA class (I to IV), HF symptoms (orthopnea, 
ankle swelling etc.), prior diagnosis of HF (Y/N), history of myocardial infarction (Y/N), 
atrial fibrillation (Y/N), arrythmia (Y/N), history of other conditions (e.g., diabetes) 
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(Y/N), history and or current depression (Y/N) and anti-depressant use (Y/N). Data on 
behavioural factors included smoking status (current smoker, never smoked, ex-smoker) 
and alcohol use (none, excess, previous excess, within the recommended limits).  
 
Anxiety and Depression 
   
Symptoms of anxiety and depression were assessed with the Hospital Anxiety and 
Depression Scale (HADS; Zigmond & Snaith, 1983). The HADS contains 14-items, 7 of 
which measure depression (HADS-D), and 7 measuring anxiety (HADS-A). Items are 
scored on a 4-point Likert scale. Scores range from 0 to 3, with a total score of 0–21 for 
each subscale. The authors suggest employing a cut-point of ≥ 8 for each of the 
constituent subscales, to indicate probable caseness. This cut-off provides sensitivity and 
specificity of 0.80 (Bjelland, Dahl, Haug & Necklemann, 2002). The Cronbach's alpha 
values are 0.83 and 0.82 for the HADS-A and HADS-D respectively, indicating the 




Perceived HR-QoL was assessed using a HF specific measure, the KCCQ (Kansas City 
Cardiomyopathy Questionnaire). The KCCQ contains 23-items which aims to quantify: 
QoL, physical limitations, social limitations, self-efficacy, symptom frequency, symptom 
burden, and symptom stability (Green, Porter, Bresnahan & Spertus, 2000). The scale 
comprises of five subscales, and all besides the self-efficacy subscale, can be used to 
compute an overall summary score. Scores for each subscale range from 0 to 100 with 
lower scores indicating worse disease-specific HR-QoL. Research has shown the KCCQ 
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to have good psychometric properties, with one study reporting a Cronbach’s alpha of 
0.92 (Creber, Polomano, Farrar & Riegel, 2012). 
 
Symptom Burden  
 
Symptom burden was measured with the Edmonton Symptom Assessment Scale (ESAS) 
(Bruera, Kuehn, Miller, Selmeser & Macmillian, 1991). The ESAS assesses nine 
symptom areas and their severity: pain, tiredness, drowsiness, lack of appetite, nausea, 
shortness of breath, fatigue, anxiety, depression and the patient's overall perception of 
their well-being. The ESAS contains 10 items, where respondents select a score between 
0 (no symptom) and 10 (represents the worst). A total score can be calculated ranging 
from 0 to 100, with higher scores indicating increased symptom burden. The ESAS was 
developed and validated for use with people living with cancer (Kaasa & Wessel, 2001). 
Nevertheless, the ESAS has been used in a study of patients with HF and the authors 
concluded the use of the ESAS alongside the KCCQ provided comprehensive 
quantitative information on patients physical and emotional distress (Opasich et al., 






















Data were analysed using the Statistical Package for the Social Sciences (SPSS, version 
26). All tests conducted were two-tailed and an alpha value of ≤.05 indicated statistical 
significance. Data were presented as Median (Md) and Interquartile Range (IQR) for non-
normally distributed continuous variables and frequencies and percentages for 
categorical variables.  
 
The characteristics of participants who completed and did not complete primary outcome 
measures (PROMs) at baseline were compared. Continuous and normally distributed 
variables were analysed using the independent t-test while non-normally distributed data 
were analysed using the Mann-Whitney U test. Differences on categorical variables were 
analysed using c2 (Chi-Square Test of Independence) or Fishers Exact test where the 
assumptions of Chi-Square were not met.  
 
Longitudinal studies are prone to missing data. Missing data was explored using the 
missing values analysis feature in SPSS (version 26). For the HADS, there was 
substantial missing data across follow-up waves. Additionally, Little’s missing at 
completely random test was significant, indicating the data were not missing completely 
at random.  
 
Consequently, it was decided that the use of multiple imputation methods would not be 
appropriate and instead analysis used observed data (i.e., listwise deletion). This 
approach is in accordance with guidance relating to the handling of missing data 
(Jakobsen, Gluud, Wetterslev & Winkel, 2017). For analysis describing the trajectory of 
anxiety and depression across follow-up, participants with four complete measurements 
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of anxiety and depression were included. For regression analysis, participants with at 
least two complete assessments of anxiety and depression were included in the analysis. 
 
Guidance stipulates that when listwise deletion methods are used to handle missing data, 
the extent of missing data should be reported on (Jakobsen et al.., 2017). See Figure 3 for 
the details of participant flow through the study. Additionally, the differences between 
participants providing one, two, three or four complete measures of anxiety and 
depression were examined using the c2 (Chi-Square Test of Independence) or Fishers 
Exact test for nominal variables. For continuous variables, differences were examined 
using one-way ANOVA for normally distributed variables or the Kruskal-Wallis Test for 
non-normally distributed variables. 
 
 
Measures of central tendency and dispersion were computed to describe the key outcome 
variables (participants anxiety and depression scores) over time (baseline, 4, 8 & 12-
month follow-up). Additionally, the proportion of participants who reported clinically 
significant symptoms of anxiety and depression was calculated at Time 1 (baseline), 
Time 2 (4-months), Time 3 (8-months) and Time 4 (12-months). The standard HADS cut 
off point of ≥8 was used to categorise participants as having clinically significant anxiety 
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Similar to previous research (Dekker et al., 2011) participants were then assigned to one 
of four anxiety and depression ‘symptom status’ groups based on the change or lack of 
change in their HADS-A and HADS-D scores from baseline to 4, 8 and 12 months (See 
Table 3). The four groups were: 1) anxiety or depression symptom-free, 2) symptoms 
improved, 3) symptoms developed, 4) and persistent symptoms.  
 
Table 3 Anxiety and Depression Symptom Status Group Assignment Based on HADS-





HADS at 4, 8, 12 months  
0-7 0-7 = Anxiety or depression symptom free  
≥8  0-7 = Anxiety or depression symptoms improved  
0-7 ≥8 = Anxiety or depression symptoms developed  
≥8 ≥8 = Persistent anxiety or depression symptoms  
 
The Friedman test was used to investigate overall change in participants depression and 
anxiety scores due to non-normal distribution. Post-hoc testing involved conducting 
individual Wilcoxon Signed Rank Tests (using Bonferroni adjusted alpha value) to 
control for Type 1 errors.  
 
Related samples Cochran’s Q tests were used to examine if there were significant 
changes in the proportion of participants reporting clinically significant anxiety and 
depression symptoms over time (baseline, 4, 8 & 12-month follow-up). The individual 
alpha level was adjusted using the Bonferroni method to control the overall experiment-
wise error rate.  
 
To explore factors associated with anxiety and depression, bivariate analysis between 
non-normally distributed continuous variables were assessed using Spearman’s rho 
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correlation coefficients. Separate standard multiple regression models were used to 
identify factors independently associated with anxiety and depression at different time 
points (4, 8 and 12-month follow-up). The independent and control variables in the 
regression models were selected based on the extant literature and included 1) sex 2) 
excess alcohol use 3) baseline KCCQ score 4) baseline ESAS score 5) antidepressant use 
and 6) history of depression. Additional independent and control variables were selected 
based on the results of bivariate analysis.  
 
Sample size requirements were estimated using guidance which asserts approximately 
15 participants per predictor are required for a well-fitting regression model (Stevens, 
1996). Therefore, a sample size of ≥120 participants was required. Multicollinearity was 
assessed using tolerance values and variance inflation factor (VIF). A tolerance value of 
<.10 suggests multicollinearity and a VIF value exceeding 10 was regarded as indicating 

















Participant Characteristics  
Medical admissions to the Western Infirmary, Glasgow during January 2013 until 
December 2014 were screened. A total of 313 HF patients were enrolled in the study. Of 




Of the 272 participants who completed PROMs at baseline, 63% and 67% had two 
complete measures, and 34% and 35% had four complete measures on the HADS-A and 
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Screening: (n = 829) with suspected 
HF  
Excluded (n = 165) 
Did not meet inclusion criteria  
 
 
Those with probable HF (n= 664) 
Enrolment 
Excluded (n= 351) 
• Confusion/dementia (n = 77) 
• Declined consent (n = 52) 
• Unable to participate (n = 47) 
• Moribund (n = 21) 
• Re-admission (n = 154) 
 
Enrolled in study   
(n= 313) 
Excluded (n= 41) 
• Did not complete PROMs 
 
Completed PROMs at 
baseline (n= 272) 
Excluded (n= 91) 
• Loss to follow-up 
• Incomplete anxiety and 
depression measures  
 
Analysis population  
 
(n = 171 participants had two complete 
measures of anxiety) 
(n = 181 participants had two complete 
measures of depression) 
(n = 92 participants had four complete 
measures of anxiety) 
(n = 95 participants had four complete 




    
 
89 
Table 4 shows baseline demographic and clinical characteristics of the sample. The 
characteristics of participants who completed at least one PROM at baseline were 
compared with non-completers. Participants who did not complete PROMS at baseline 
were older (Md = 84.24; p < .001), were more likely to have a history of cancer c2 (1, n 
= 313) = .4.20, p = .040, phi = .130, were less likely to experience wheezing (p = .022) 
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Table 4 Baseline Demographic and Clinical Characteristics of Participants  
 
 Full Sample  
N = 313 
 
Completed PROMS at baseline  
N = 272 
 
Did not complete PROMS at 
baseline  





 (70.6, 83.4) 
75.99 
 (69.8, 82.4) 
 
84.24 












South Asian  
Black  
White  
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HF diagnosis prior to 



















Ejection Fraction  
< 50% 
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Smoking History  
Current  





















Alcohol History  
None 
Excess  
























Note: Categorical variables are denoted as N and (%) Continuous variables are represented by Median and (Interquartile Range). P values were calculated using Mann 
Whitney U test for non-normally distributed continuous variables and the chi-square test of association for categorical variables. If the frequency in a cell was <5, p-values 
were calculated using Fishers exact probability test. For variables with a 2 by 2 table Yates’ Correction for Continuity value is presented. Bolded values highlight 
statistically significant differences. † Denotes that valid percentages are reported.  
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Tables 5 & 6 in Appendix 2.5, p.166-169 describe the demographic and clinical 
characteristics of participants with one, two, three and four complete measurements of 
anxiety and depression. The baseline characteristics of participants who completed the 
HADS at baseline were compared to those with two, three and four complete 
measurements.  
 
Participants who provided four measures of anxiety were more likely to have been 
diagnosed with CHF prior to the index admission c2 (3, n = 233) = 7.847, p = .049, phi 
= .184 compared to participants who completed HADS-A at baseline only. There was a 
significant association between baseline anti-depressant use and HADS-D completion 
status (p = .026). A higher proportion of participants with two complete measures of 
depression (at baseline and 4-months) were prescribed anti-depressant medication 
compared to participants with four complete measures (20.9% vs 6.3% respectively). 
Participants who completed HADS-D at baseline were more likely to report no alcohol 
use compared to participants with four complete measures (p = .012).  
 
There was a trend, although not statistically significant for a lower proportion of 
participants with higher NYHA class (Class IV) to provide four HADS-D measurements, 
c2 (6, n = 238) = 12.517, p = .051, phi = .229.  Specifically, 21.1% of participants who 
completed HADS-D at baseline only were classified as NYHA Class IV compared to 
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Anxiety and Depression Over Time  
 
 
Participants’ anxiety scores at baseline, 4, 8 and 12-months were non-normally 
distributed, with skewness values of: .631 (SE = .251), .839 (SE = .251), 1.119 (SE = 
.251), and .919 (SE = .251) respectively. Depression scores at baseline, 4, 8 and 12-
months were also non-normally distributed, with skewness values of: .531 (SE = .247), 
.517 (SE = .247), .796 (SE = .247) and .782 (SE = .247) respectively. Inspection of 






There was a statistically significant difference in HADS-A scores across the four time 
points (baseline, 4, 8 and 12-month follow-up) c2 (3, n = 92) = 18.514, p <.001. Post-hoc 
pairwise comparisons were conducted using four Wilcoxon Signed Rank tests, applying 
the Bonferroni adjustment to correct for problems caused by multiple comparisons 
(corrected alpha = .0125). Results indicated a statistically significant reduction in anxiety 
scores from baseline to 4-months, z = -2.520, p = .012, with a small effect size (r = 0.19). 
Anxiety scores did not differ significantly between 4- and 8-month follow-up, z = -.233, 
p = .816 or between 8 and 12-month follow-up, z = -2.042, p = .041. There was a 
significant reduction in anxiety scores from baseline to 12-month follow-up, -4.088, p < 
.001, with a medium effect size (r = 0.30). As can be seen in Table 7 the median score 
on the HADS-A scale decreased from baseline (Md = 6) to 4-month follow-up (Md = 4) 









There were no statistically significant differences in HADS-D scores across the four time 
points (baseline, 4, 8 and 12-month follow-up) c2 (3, n =95) = 2.957, p = .398. As can be 
seen from Table 7 the median score on the HADS-D remained stable (Md = 6) between 
baseline, 4 and 8-month follow-up.  
 
Table 7 Medians (MD) and Interquartile Range (IQR) for Participants Symptoms of 
Anxiety and Depression at Baseline (Time 1), 4-Month (Time 2), 8-Month (Time 3) and 
12-Month Follow-up (Time 4).  
 










6.00 (3.25, 9.00) 4.00 (2.00, 9.00) 5.00 (2.00, 8.00) 3.00 (3.00, 7.75) 
HADS-D TOTAL 
SCORE  
6.00 (3.00, 9.00) 6.00 (2.00, 
10.00) 
6.00 (3.00, 9.00) 5.00 (2.00, 8.00) 
 
To examine if there were significant changes in the proportion of participants with and 
without clinically significant anxiety and depression over time (baseline, 4, 8 and 12-
month follow-up) related samples Cochran’s Q tests were conducted. There was a 
statistically significant difference in the proportion of participants with clinically 
significant anxiety symptoms over time, c2 (3) = 19.97, p <.001. Pairwise comparisons, 
indicated significant differences between time 1 (baseline) and time 2 (4-month follow-
up) (p = .005), time 1 (baseline) and time 3 (8-month follow-up) (p = .005) and time 1 
(baseline) and time 4 (12-month follow-up) (p < .001). As can be seen in Figure 4 the 
proportion of participants reporting clinically significant symptoms of anxiety decreased 
from 43.5% at baseline to 25.0% at 12-month follow-up.  
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Results also revealed a significant difference in the proportion of participants with 
clinically significant depression symptoms over time, c2 (3) = 8.13, p = .04. Pairwise 
comparisons, indicated significant differences between time 1 (baseline) and time 4 (12-
month follow-up) (p < .01) and time 3 (8 month) and time 4 (12-month follow-up) (p = 
.028). As can be seen in Figure 5 the proportion of participants reporting clinically 
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Figure 4 & 5 Proportion of Participants With and Without Clinically Significant Anxiety and Depression Symptoms at Baseline (Time 1), 4-Month 



























Figure 4. Proportion of Participants With and Without Clinically 
Significant Symptoms of Anxiety 






















Figure 5. Proportion of Participants With and Without Clinically 
Significant Symptoms of Depression 
No clinically significant symptoms (HADS-D < 8) Clinically significant symptoms (HADS-D ≥8)
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Trajectories of Anxiety and Depression   
 
Using an approach described in previous research (Dekker et al., 2011), participants were 
assigned to one of four symptom status groups based on the change of their HADS score 
at baseline compared to 4-, 8- and 12-month follow-up (See Table 3).  
 
As can be seen from Figure 6, 7 and 8 from baseline to 4, 8 and 12-month follow-up 
between 48-50 participants remained anxiety symptom free, while 17-20 experienced 
improvement in their anxiety symptoms, 2-4 had developed anxiety symptoms, and 20-
23 reported persistent anxiety symptoms.  
 
Additionally, review of Figures 9, 10 and 11 depicts that from baseline to 4, 8 and 12-
month follow-up between 48-51 participants remained depression symptom free, while 
11-18 experienced improvement in their depression symptoms, 6-9 had developed 























































Symptom free (n = 49) Symptoms improved (n = 17) Symptoms developed (n = 3) Persistent symptoms (n = 23)













Symptom free (n = 48) Symptoms improved (n = 19) Symptoms developed (n = 4) Persistent symptoms (n = 21)













Symptom free (n = 50) Symptoms improved (n = 20) Symptoms developed (n = 2) Persistent symptoms (n = 20)
Figure 8. Anxiety Symptom Status Change from Baseline to 12-Month 
Follow-up









































Symptom free (n = 49) Symptoms improved (n = 14) Symptoms developed (n = 8) Persistent symptoms (n = 24)












Symptom free (n = 48) Symptoms improved (n = 11) Symptoms developed (n = 9) Persistent symptoms (n = 27)













Symptom free (n = 51) Symptoms improved (n = 18) Symptoms developed (n = 6) Persistent symptoms (n = 20)
Figure 11. Depression Symptom Status Change from Baseline to 12-Month 
Follow-up 
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Factors Associated with Anxiety and Depression  
 
Results of bivariate correlations between continuous variables using Spearman’s rho 
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Baseline depression 
score  
  .206** .525** 
        
Anxiety score at 4-
months 
.122 .634** 406** 
       
Depression score at 
4-months 
.122 .391** .612** 
       
Anxiety score at 8-
months 
.044 643** .353** 
       
Depression score at 
8-months 
.002 .445** .647** 
       
Anxiety score at 12-
months  
.052 .570** .280** 
       
Depression score at 
12-months  
-.055 222* .600** 
       
Baseline symptom 
burden score (ESAS) 




-.107 -.379** -.531** -.220** -.357** -.226* -.417** -.249* -.397** -.496** 
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Predictors of Anxiety and Depression  
 
 
The dependent variables anxiety and depression scores at 4-month, 8-month and 12-
month follow-up were regressed on eight independent and control variables (anti-
depressant use, history of depression, sex, excess alcohol use, baseline anxiety and 
depression score, baseline symptom burden and baseline KCCQ summary score), using 
standard multiple regression. The variables were entered into the model simultaneously. 
Preliminary analyses were conducted to ensure no violation of the assumptions of 
normality of residuals, linearity, multicollinearity, and homoscedasticity.   
 
Predictors of Anxiety and Depression at 4-month follow-up  
The results of the anxiety model were significant: F (8, 162), = 20.323, p < .001. Adjusted 
R2 was found to be .476, indicating the model accounted for 47.5% of the variance in 
participants anxiety scores at 4-months. As can be seen from table nine, baseline KCCQ 
summary score (standardised β = .225, p < .01) and baseline anxiety score (standardised 
β = .616, p < .001) independently predicted anxiety at 4-months.  
 
The results of the depression model were also significant: F (8, 168), = 15.21, p = < .001. 
Adjusted R2 was found to be .392, indicating the model accounted for 39.2% of the 
variance in participants depression scores at 4-months. As can be seen from table nine, 
depression score at baseline (standardised β = -601, p < .001) and anti-depressant use 
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Predictors of Anxiety and Depression at 8-month follow-up  
The results of the anxiety model were significant: F (8, 139), = 17.662, p < .001. Adjusted 
R2 was found to be .476, indicating the model accounted for 47.5% of the variance in 
participants anxiety scores at 8-months.  As can be seen from table nine, baseline anxiety 
(standardised β =.620, p < .001) and depression history (standardised β = .277, p = < 
.001) independently predicted participants anxiety at 8-month follow-up.  
 
 
Additionally, the results depression model was significant: F (8, 141), = 13.636, p < .001. 
Adjusted R2 was found to be .397, indicating overall the model accounted for 39.7% of 
the variance in participants depression scores at 8-months. As can be seen from table 
nine, depression score at baseline (standardised β = .489, p < .001) and history of 




Predictors of Anxiety and Depression at 12-month follow-up  
The results of the anxiety model were significant: F (8, 115), = 12.730, p < .001. Adjusted 
R2 was found to be .433, indicating overall the model accounted for 43.3% of the of the 
variance of in participants anxiety scores at 12-months. As can be seen from table nine, 
female sex (standardised β = -.162, p = .025), depression history (standardised β = .163, 
p = .020) and baseline anxiety score (standardised β = .591, p < .001) independently 
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Additionally, the results of the depression model were significant: F (8, 122), = 9.423, p 
< .001. Adjusted R2 was found to be .356, indicating overall the model accounted for 
35.6% of the variance in participants depression scores at 12-months. As can be seen 
from table nine, female sex (standardised β = -.226, p = .004), and baseline depression 
score (standardised β = .552, p < .001) independently predicted depression at 12-months.  
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Table 9 Variables Associated with Anxiety and Depression  
 
 Variable Standardised β 
 
t 95% CI p-value 
Dependent Variable: 
Anxiety at 4-months  




































































 Baseline depression  
 
.108 1.387 -.051–.292 .167 
Dependent Variable: 
Depression at 4-months  




-.721 -1.393–.648 .472 




.791 -1.522–3.556 .430 




.152 -.028–.032 .880 




.573 -.022–.040 .567 




2.469 .554–4.972 .015 
 Depression history  
 
.082 1.379 -.441–2.486 .170 
 Baseline anxiety  .039 .502 -.104–.174 .617 
 Baseline depression  .601 7.31 .461–.803 <.001 
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 Variable Standardised β 
 
t 95% CI P-value 
Dependent Variable: 
Anxiety at 8-months  














1.322 -.930– 4.680 .188 
 




1.754 -.004–.063 .082 
 











.174 -2.226– 2.656 .862 






1.444 – 4.678 < .001 
 








 Baseline depression 
 
.046 .547 -.136–.241 .586 
Dependent Variable: 
Depression at 8-months  
Female vs Male sex 
 
-.055 -.843 -1.629–.655 .401 
 Excess alcohol use 
 
.040 .619 -1.950–3.730 .537 
 Baseline ESAS score 
 
.044 .534 -.025–.043 .594 
 





-.600 -.045–.024 .550 
 Anti-depressant use 
 
.057 .869 -1.385– 3.557 .386 
 Depression history 
 
.134 2.092 .095– 3.369 .038 
 Baseline anxiety .138 1.667 -.024–.287 .098 
 Baseline depression 
 
.489 5.528 .343–.725 < .001 
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 Variable Standardised β 
 
t 95% CI P-value 
Dependent Variable: 
Anxiety at 12-months  






-2.802 – -.190 
 
.025 




-.370 -2.512–1.721 .712 
 




1.817 -.003–.073 .072 
 










-.007 -2.775–2.756 .995 




2.364 .354–4.012 .020 
 






 Baseline depression  
 
.076 .800 -.128–.301 .425 
Dependent Variable: 
Depression at 12-months  
Female vs Male gender 
 
-.226 -2.965 -3.195– -.635 .004 
 Excess alcohol use  
 
-.022  -.288 -2.375–1.772 .774 
 Baseline ESAS score  
 
.038 .399 -.030–.045 .690 
 





.-.435 -.046–.030 .664 
 Anti-depressant use  
 
.095 1.259 -.987–4.431 .211 
 Depression history  
 
.038 .510 -1.330–2.253 .611 
 Baseline anxiety -.025 -.259 -.193–.148 .796 
 Baseline depression  
 
.552 5.430 .365–.785 < .001 





The primary aim of the study was to examine and describe the trajectories of anxiety and 
depression in patients with CHF over 12-month follow-up. At the group level, there were 
significant reductions in median anxiety scores between baseline (index admission) and 
4 and 12-month follow-up. There was also a significant decrease in the proportion of 
participants reporting clinically significant anxiety from baseline/index admission 
(43.5%), compared to (25.0%) at 12-months. Additionally, more than half of the sample 
remained anxiety ‘symptom’ free during follow-up and one in five participants, who 
reported anxiety at baseline experienced symptom resolution (scores fell below HADS 
cut-off) by 4 to 12 months. This pattern may be indicative of a transient adjustment 
response, with higher rates of anxiety at baseline representing an emotional reaction to 
hospitalisation or decline in health/functioning. These findings are consistent with the 
working model of adjustment (Moss-Morris, 2013) which asserts critical events 
including hospitalisation, diagnosis or relapse/disease progression disrupts an 
individual’s ‘emotional equilibrium’ leading to distress.  
 
Results also indicated 25% of the sample reported anxiety symptoms at 12-months, and 
between 21.7% to 25% of participants, who reported clinically significant anxiety at 
baseline experienced persistent symptoms across follow-up phases. Furthermore, a small 
proportion between 2.2% to 4.3% developed anxiety during the follow-up period. These 
findings are consistent with previous research which found approximately 30% of people 
with CHF report clinically significant anxiety symptoms (based on self-report measures) 
(Easton et al., 2016).  
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In terms of depression, there were no statistically significant reductions in participants 
median depression scores at baseline (index admission) and 4, 8 and 12-month follow-
up. Nevertheless, results showed a significant decrease in the proportion of participants 
reporting clinically significant depression symptoms from their index admission 
(baseline) 40.0% compared to 27.4% at 12-months. This finding is consistent with 
research reporting higher rates of depression among people hospitalised with CHF 
compared to outpatients experiencing a period of stability in their HF symptoms 
(Konstam et al., 2005).  
 
Additionally, over half of the sample, remained depression ‘symptom free’, and 14.7%, 
11.6% and 18.9% who reported depression symptoms at baseline experienced symptom 
resolution by 4-, 8- and 12-month follow-up respectively. This pattern could be indicative 
of a transient adjustment response, with higher rates of depression at baseline 
representing an emotional reaction to a critical event (e.g., hospitalisation, receiving a 
diagnosis or disease progression) (Moss-Morris, 2013). 
 
These findings are consistent with results from a previous study which examined the 
trajectories of depression in a sample of inpatients and outpatients with CHF. Dekker and 
colleagues (2011) found 64% of the sample were classified as ‘depressive symptom free’, 
and 15% of participants who reported depression at baseline recovered after three to six 
months.  
 
Results also revealed 6.3% of participants who were ‘depressive symptom free’ at 
baseline reported a clinically significant increase in symptoms at 12-month follow-up. 
These findings are consistent with Dekker and colleagues (2011) study which found 6% 
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had developed symptoms of depression at 3-or 6-month follow-up. For participants who 
reported clinically significant symptoms of depression at baseline, between 21.1% and 
28.4% experienced persistent symptoms of depression at 12-month and 8-month follow-
up respectively. The proportion of the sample experiencing persistent depression is 
higher than one study reporting 15% of CHF patients experienced persistent depression 
(Dekker et al., 2011), and lower than Johansson and colleagues (2013) study which found 
39% reported persistent depression. The difference in findings between the present study 
and the aforementioned research may be explained by variance in the duration of follow-
up, sample size and self-report measures used to assess depression across the studies.  
 
The second aim of this study was to identify demographic and clinical factors that were 
independently associated with anxiety and depression in CHF patients during 12-month 
follow-up. Results showed baseline KCCQ summary score, baseline anxiety score (at 4-
month follow-up), baseline anxiety and history of depression (at 8-month follow-up) and 
female sex, history of depression and baseline anxiety (at 12-month follow-up) 
independently predicted anxiety. These findings are consistent with studies which found 
reduced HR-QoL, and presence or history of depression predicted anxiety CHF patients 
(Allabadi et al., 2019; Årestedt et al., 2014).   
 
 
In terms of depression, factors including baseline depression score and anti-depressant 
use (at 4-month follow-up), history of depression (at 8 month-follow-up) and female sex 
and baseline depression (at 12-month-follow-up) predicted depression. These findings 
are consistent with previous research which found premorbid factors including past 
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history of distress and anti-depressant treatment predicted depression outcome trajectory 
in CHF patients at 12-week follow-up (Koenig et al., 2006).  
 
Nevertheless, the results are not consistent with research which found behavioural factors 
including (excess alcohol use) and baseline HR-QoL predicted depression at 12-month 
follow-up in HF patients (Havranek et al., 2004). The mixed findings may be partially 
explained by differences between the samples. In the present study a relatively low 
proportion (6.3% of participants with four complete depression measurements) reported 
excess alcohol use compared to between 11.4% to 23.1% of the sample recruited by 





This study has a number of strengths. First, the data used in this secondary analysis were 
collected by approaching a largely consecutive cohort of patients hospitalised for 
suspected CHF (Campbell et al, 2015), which reduced the risk of selection bias.  
 
Second, the recruited sample included a relatively equal number of men and women 
participants. This is a key strength as although data have shown the incidence of CHF is 
similar among men and women (Go et al., 2014), women are underrepresented in studies 
of HF (Pressler, 2016). Consequently, there is increased confidence the study’s findings 
can be extrapolated to female CHF populations. Additionally, the present study addressed 
some of the limitations of previous research by simultaneously describing the time-
course of anxiety and depression in CHF patients, as opposed to previous research 
focusing on depression only (Volz et al., 2011).  




A number of limitations of the study must be acknowledged and the findings should be 
interpreted with caution. First, a considerable number of participants were excluded from 
the analysis due to not having complete data on baseline or follow-up measurements of 
anxiety and depression. It has been acknowledged longitudinal studies are prone to 
incomplete data/participant drop out as procedures including completing outcome 
measures or attending study visits can become more demanding for participants as their 
CHF progresses (Campbell et al., 2015).  
 
Analysis revealed a lower proportion of participants with four measures of depression 
used anti-depressant medication compared to participants who had two complete 
measures. There was also a trend, although not statistically significant, for a lower 
proportion of participants with four complete measures of depression and anxiety to be 
classified as NYHA Class IV compared to participants who had completed measures at 
baseline. This may have resulted in a bias towards participants who experienced less 
severe CHF symptoms/functional limitations or levels of emotional distress.  Therefore, 
the findings may not be generalisable to CHF patients experiencing the most severe 
functional limitations or those with levels of emotional distress requiring psychotropic 
medication.  
 
Nevertheless, analysis revealed no significant differences in the proportion of 
participants who reported anxiety and depression at baseline (defined as HADS ≥8) 
between participants completing one measure of anxiety and depression and those 
providing four measures. There were no significant differences on demographic and 
clinical characteristics including age, sex, presence of HF symptoms, history of 
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depression, baseline symptom burden, cardiac factors (e.g., history of arrythmias) and 
presence of co-occurring health issues (e.g., diabetes). Therefore, reducing concerns of 
presence of wider systematic bias.  
 
Second, most participants were Caucasian, and the findings might not be generalisable 
to other ethnic groups. Additionally, participants who did not complete outcome 
measures at baseline were older compared to completers. This is consistent with general 
issues in the HF literature which notes although HF is more common in people aged 80 
or older (Go et al., 2014), the mean age of people recruited in CHF studies was 61.4 years 
(Heiat, Gross & Krumholz, 2002). The median age of participants completing four 
measures of anxiety was 74, suggesting older adults were represented in this sample. 
Nevertheless, the results may not generalise to older adults (over the age of 75).  
 
Third, the data analytic methods used to describe the time-course of anxiety and 
depression symptoms over time have limitations. Some assert the examination of overall 
change in anxiety or depression scores at the group level, assumes all participants recover 
in a homogenous, linear fashion (Murphy et al., 2008). It is conceivable while anxiety 
and depression improves over time for the majority of patients, for others emotional 
distress may persist or worsen over-time. Therefore, the statistical methods in this study 
were limited because they did not enable recognition of multiple trajectories of change 
in distress over-time.   
 
Similarly, the current study’s examination of change in the proportion of participants 
presenting with clinically significant anxiety and depression over time and assignment of 
participants into four symptom status change groups has limitations. This method does 
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not allow the identification or characterisation of multiple trajectories of change in 
anxiety and depression over time (Murphy et al., 2008). The study also relied on applying 
a clinical cut off (≥8 on the HADS) to 1) classify participants as having clinically 
significant anxiety and depression and 2) allocate participants into one of the four 
symptom status change groups. Some assert the use of cut offs might not accurately 
reflect or provide a nuanced picture of change in the patients’ experience (Murphy et al., 
2008). 
 
Finally, as this was a secondary data analysis, there was no available information on 
participants' history of anxiety or past treatment with psychological therapy. There was 
also no data collected on psychosocial factors which may influence emotional adjustment 
in CHF populations including coping styles and cognitive illness perceptions. 
Consequently, the exploration of factors associated with anxiety or depression was 
restricted to non-modifiable clinical and demographic characteristics.  
 
Research Implications  
 
The present study identified some clinical risk factors (history of depression or 
psychotropic medication use), which predicted distress in this cohort of CHF patients. 
Future research is required to identify the demographic, social or psychological factors 
(e.g., cognitive appraisals), which might mediate the relationship between clinical history 
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Future research in this area should be underpinned by theoretical models of emotional 
adjustment to chronic illness. As this study was a secondary analysis, the outcome 
measures analysed were selected due to availability of data as opposed to being guided 
by psychological models of adjustment. Further research is required to test out 
predictions of the working model of adjustment including the influence that 
social/environmental factors, cognitive factors and behavioural factors (Moss-Morris, 
2013) have on the emotional adjustment trajectories of CHF patients. Future research 
could measure operationalised variables including presence of social support, socio-
economic status, perceptions of stress, negative illness representations (e.g., perceptions 
of control), avoidant coping and experiential avoidance/repression of emotions using 
validated measures. Collecting data on these factors may help to explain individual 
differences in emotional adjustment trajectories following hospital admission in CHF 
patients.  
 
Some social, cognitive and behavioural factors are potentially modifiable and future 
research examining the relationship between these factors, critical events/on-going 
illness stressors and emotional outcomes could elucidate the psychosocial characteristics 
of patients at greater risk for prolonged distress and inform targets for supportive 
interventions.  
 
Additionally, as described above the data analytic methods used in this study have 
limitations.  Future research could consider using techniques such as latent class analysis 
or growth modelling techniques to identify and describe multiple or non-linear 
trajectories of change in anxiety and depression in CHF patients over time. 
Characterising and understanding anxiety and depression symptom trajectories and the 
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factors/characteristics associated with these trajectories is required to inform the optimal 
timing of screening for emotional distress, and to inform preventative strategies to 
improve CHF patients’ quality of life.  
 
Finally, a larger multi-centre study, recruiting participants from Black, Asian and 
Minority Ethnic backgrounds is required to replicate the findings and to enhance the 
cultural validity and generalisability of the findings.  
 
 
Conclusion   
 
To conclude, this study found a significant reduction in the proportion of CHF patients 
reporting anxiety and depression symptoms from baseline (hospital admission for HF) to 
12-month follow-up. This may be indicative of a transient adjustment response, with 
higher rates of anxiety and depression observed at baseline representing an emotional 
reaction to hospitalisation or decline in health/functioning. There was also a subset of 
participants that experienced persistent anxiety and depression symptoms during follow-
up, while a small proportion who were ‘symptom free’ at baseline went on to develop 
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Relevance to Clinical Practice  
 
The findings of this study contribute to the literature by describing the trajectory of 
anxiety and depression symptoms in people with CHF, a subject which has been 
relatively neglected (Voltz et al., 2011; Johansson et al., 2013). Overall, results indicated 
most participants remained anxiety and depression symptom free or experienced 
resolution in their anxiety and depression symptoms during follow-up. Nevertheless, 
there was a proportion of participants who experienced persistent anxiety and depression 
symptoms during 12-month follow-up. Accordingly, routine and repeated screening, for 
anxiety and depression in outpatient settings or primary care may be warranted to identify 
CHF patients who do not experience a transient adjustment response following 
hospitalisation. Additionally, findings revealed: history of depression, female sex and 
HR-QoL at baseline predicted anxiety during follow-up. While, female sex, history of 
depression and anti-depressant use predicted depression during the follow-up period. 
Therefore, it may be most critical to screen for anxiety and depression among female 
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The Journal of Clinical Nursing (JCN) is an international, peer reviewed, scientific journal that 
seeks to promote the development and exchange of knowledge that is directly relevant to all 
spheres of nursing practice. The primary aim is to promote a high standard of clinically related 
scholarship which advances and supports the practice and discipline of nursing. The Journal 
also aims to promote the international exchange of ideas and experience that draws from the 
different cultures in which practice takes place. Further, JCN seeks to enrich insight into 
clinical need and the implications for nursing intervention and models of service delivery. 
Emphasis is placed on promoting critical debate on the art and science of nursing practice. 
 
JCN is essential reading for anyone involved in nursing practice, whether clinicians, 
researchers, educators, managers, policy makers, or students. The development of clinical 
practice and the changing patterns of inter-professional working are also central to JCN's scope 
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objectives; Background, Design; Methods; Results (do not report p values, confidence 
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https://onlinelibrary.wiley.com/page/journal/13652702/homepage/forauthors.html#editorial 
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Crowe Critical Appraisal Tool (CCAT) Form (v1.4) Reference  Reviewer  





Research design (add if not listed) 
❏ Not research Article  |  Editorial  |  Report  |  Opinion  |  Guideline  |  Pamphlet  |  …  
❏ Historical …  




A. Cross-sectional  |  Longitudinal  |  Retrospective  |  Prospective  |  Correlational  |  Predictive  |  …  
B. Cohort  |  Case-control  |  Survey  |  Developmental  |  Normative  |  Case study  |  …  
Experimental 
❏ True  
experiment 
Pre-test/post-test control group  |  Solomon four-group  |  Post-test only control group  |  Randomised two-factor  | 
Placebo controlled trial  |  …  
❏ Quasi- 
experiment 
Post-test only  |  Non-equivalent control group  |  Counter balanced (cross-over)  |  Multiple time series  | 
Separate sample pre-test post-test [no Control] [Control]  |  …  
❏ Single  
system 
One-shot experimental (case study)  |  Simple time series  |  One group pre-test/post-test  |  Interactive  |  Multiple baseline  | 
Within subjects (Equivalent time, repeated measures, multiple treatment)  |  …  
❏ Mixed Methods Action research  |  Sequential  |  Concurrent  |  Transformative  |  …  
❏ Synthesis Systematic review  |  Critical review  |  Thematic synthesis  |  Meta-ethnography  |  Narrative synthesis  |  …  
❏ Other …  
 
Variables and analysis 
Intervention(s), Treatment(s), Exposure(s) Outcome(s), Output(s), Predictor(s), Measure(s) Data analysis method(s) 
   
 
Sampling 





















Data collection (add if not listed) 
Audit/Review 
a) Primary  |  Secondary  |  … 
b) Authoritative  |  Partisan  |  Antagonist  |  … 
c) Literature  |  Systematic  |  … 
Interview 
a) Formal  |  Informal  |  … 
b) Structured  |  Semi-structured  |  Unstructured  |  … 
c) One-on-one  |  Group  |  Multiple  |  Self-administered  |  … 
Observation 
a) Participant  |  Non-participant  |  … 
b) Structured  |  Semi-structured  |  Unstructured  |  … 
c) Covert  |  Candid  |  … 
Testing 
a) Standardised  |  Norm-ref  |  Criterion-ref  |  Ipsative  |  … 
b) Objective  |  Subjective  |  … 
c) One-on-one  |  Group  |  Self-administered  |  … 
 
Scores 
Preliminaries  Design  Data Collection  Results  Total [/40]  
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[! Present;  " Absent;  ■ Not applicable] 
Description 
[Important information for each item] 
Score 
[0–5] 
1. Preliminaries   
Title 1. Includes study aims ❏ and design ❏  
Abstract 
(assess last) 
1. Key information ❏ 




1. Sufficient detail others could reproduce ❏ 
2. Clear/concise writing ❏, table(s) ❏, diagram(s) ❏, figure(s) ❏ 
 
  Preliminaries [/5]  
2. Introduction   
Background 1. Summary of current knowledge ❏ 
2. Specific problem(s) addressed ❏ and reason(s) for addressing ❏ 
 
Objective 1. Primary objective(s), hypothesis(es), or aim(s) ❏ 
2. Secondary question(s) ❏ 
 
 Is it worth continuing? Introduction [/5]  
3. Design   
Research design 1. Research design(s) chosen ❏ and why ❏ 




1. Intervention(s)/treatment(s)/exposure(s) chosen ❏ and why ❏ 
2. Precise details of the intervention(s)/treatment(s)/exposure(s) ❏ for each group ❏ 




1. Outcome(s)/output(s)/predictor(s)/measure(s) chosen ❏ and why ❏ 
2. Clearly define outcome(s)/output(s)/predictor(s)/measure(s) ❏ 
3. Outcome(s)/output(s)/predictor(s)/measure(s) valid ❏ and reliable ❏ 
 
Bias, etc 1. Potential bias ❏, confounding variables ❏, effect modifiers ❏, interactions ❏ 
2. Sequence generation ❏, group allocation ❏, group balance ❏, and by whom ❏ 
3. Equivalent treatment of participants/cases/groups ❏ 
 
 Is it worth continuing? Design [/5]  
4. Sampling   
Sampling method 1. Sampling method(s) chosen ❏ and why ❏ 
2. Suitability of sampling method ❏ 
 
Sample size 1. Sample size ❏, how chosen ❏, and why ❏ 
2. Suitability of sample size ❏ 
 
Sampling protocol 1. Target/actual/sample population(s): description ❏ and suitability ❏ 
2. Participants/cases/groups: inclusion ❏ and exclusion ❏ criteria 
3. Recruitment of participants/cases/groups ❏ 
 
 Is it worth continuing? Sampling [/5]  
5. Data collection   
Collection method 1. Collection method(s) chosen ❏ and why ❏ 
2. Suitability of collection method(s) ❏ 
 
Collection protocol 1. Include date(s) ❏, location(s) ❏, setting(s) ❏, personnel ❏, materials ❏, processes ❏ 
2. Method(s) to ensure/enhance quality of measurement/instrumentation ❏ 
3. Manage non-participation ❏, withdrawal ❏, incomplete/lost data ❏ 
 
 Is it worth continuing? Data collection [/5]  
6. Ethical matters   
Participant ethics 1. Informed consent ❏, equity ❏ 
2. Privacy ❏, confidentiality/anonymity ❏ 
 
Researcher ethics 1. Ethical approval ❏, funding ❏, conflict(s) of interest ❏ 
2. Subjectivities ❏, relationship(s) with participants/cases ❏ 
 
 Is it worth continuing? Ethical matters [/5]  
7. Results   
Analysis, Integration, 
Interpretation method 
1. A.I.I. method(s) for primary outcome(s)/output(s)/predictor(s) chosen ❏ and why ❏ 
2. Additional A.I.I. methods (e.g. subgroup analysis) chosen ❏ and why ❏ 
3. Suitability of analysis/integration/interpretation method(s) ❏ 
 
Essential analysis 1. Flow of participants/cases/groups through each stage of research ❏ 
2. Demographic and other characteristics of participants/cases/groups ❏ 




1. Summary of results ❏ and precision ❏ for each outcome/output/predictor/measure 
2. Consideration of benefits/harms ❏, unexpected results ❏, problems/failures ❏ 
3. Description of outlying data (e.g. diverse cases, adverse effects, minor themes) ❏ 
 
  Results [/5]  
8. Discussion   
Interpretation 1. Interpretation of results in the context of current evidence ❏ and objectives ❏ 
2. Draw inferences consistent with the strength of the data ❏ 
3. Consideration of alternative explanations for observed results ❏ 
4. Account for bias ❏, confounding/effect modifiers/interactions/imprecision ❏ 
 
Generalisation 1. Consideration of overall practical usefulness of the study ❏ 
2. Description of generalisability (external validity) of the study ❏ 
 
Concluding remarks 1. Highlight study’s particular strengths ❏ 
2. Suggest steps that may improve future results (e.g. limitations) ❏ 
3. Suggest further studies ❏ 
 
  Discussion [/5]  
9. Total   
Total score 1. Add all scores for categories 1–8  
  Total [/40]  
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Appendix 1.6 CCAT Quality Ratings   
 
Author/Year Preliminaries Introduction Design Sampling Data 
collection 
Ethics Results Discussion Total score 
(%) 
Descriptive 
1.Amiaz et al., 
2016 
3/5 4/5 2/5 2/5 3/5 2/5 2/5 3/5 20/40(53%) 
 
Moderate 
2.Amiaz et al., 
2017  
4/5 4/5 4/5 2/5 2/5 2/5 3/5 4/5 25/40(63%) Moderate 
3.Farahani et 
al., 2016  
 




al., 2017b  
 
4/5 4/5 3/5 3/5 3/5 3/5 2/5 4/5 26/40(65%) Moderate 
5. Habibović et 
al., 2018  
 
4/5 5/5 3/5 3/5 4/5 3/5 2/5 4/5 27/40(70%) Moderate 
6. Ichikura et 
al., 2017  
 
4/5 5/5 2/5 3/5 3/5 2/5 2/5 3/5 24/40(60%) Moderate 
7.Israelsson et 
al., 2018  
 
4/5 3/5 2/5 3/5 3/5 2/5 3/5 3/5 23/40(58%) Moderate 
8. Lee et al., 
2020 
4/5 4/5 2/5 2/5 3/5 3/5 3/5 4/5 25/40(63%) Moderate 
9. Miller, 
Thylén & 
Moser 2016  
 
4/5 4/5 2/5 3/5 3/5 2/5 3/5 4/5 25/40(63%) Moderate 
10. Pedersen et 
al., 2018  
3/5 4/5 3/5 3/5 4/5 3/5 2/5 3/5 25/40(63%) Moderate 
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Author/Year Preliminaries Introduction Design Sampling Data 
collection 
Ethics Results Discussion Total score Descriptive 
11.Rahmawati 
et al., 2016 
 
3/5 4/5 2/5 3/5 2/5 3/5 2/5 3/5 22/40(55%) 
 
Moderate 
 12. Rottmann 
et al., 2018  
 
3/5 4/5 3/5 3/5 3/5 3/5 2/5 4/5 25/40(63%) Moderate 
13.Starrenburg 
et al., 2014 
 
 
4/5 4/5 3/5 3/5 3/5 2/5 3/5 4/5 26/40(65%) 
 
Moderate 
14. Thylén et 
al., 2014  
 
4/5 5/5 2/5 3/5 3/5 3/5 3/5 4/5 27/40(68%) Moderate 
15. Thylén et 
al., 2016  
 
4/5 4/5 2/5 3/5 3/5 3/5 3/5 4/5 26/40(65%) Moderate 
16. Varghese, 
Geller & Ohlow 
2019  
 
3/5 2/5 3/5 2/5 3/5 2/5 3/5 2/5 19/40(48%) Low 
17.Wong 2016  
 
3/5 3/5 2/5 2/5 2/5 2/5 2/5 3/5 19/40(48%) Low 
 18. Wong 2018 3/5 3/5 2/5 2/5 2/5 2/5 2/5 3/5 19/40(48%) Low 
19. Wong 2019  
 
2/5 4/5 2/5 2/5 2/5 2/5 2/5 3/5 19/40(48%) Low 
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Appendix 2.1 Original Major Research Proposal (MRP) V2 
 
 
Doctorate in Clinical Psychology Submission Front page 
 
Assignment: Module 8 Major Research Project Proposal  
Matriculation number: 2428474D 
Date of submission: 16/12/2019 
Version number: 2 
Word count:  3000 (excluding appendices and references) 
Maximum word count: 3000 words.  
 
Title: An Investigation into the Sociodemographic, Clinical and 
Psychological Variables Influencing Psychological Adjustment and Health 
























Implantable cardioverter defibrillators (ICDs) are lifesaving devices used to treat abnormal ventricular 
arrhythmias. Nevertheless, a sub-set of ICD recipients experience psychological adjustment difficulties 
and impaired health-related quality of life (HR-QOL). Research has identified socio-demographic, 
clinical and psychological variables associated with distress and reduced HR-QOL among ICD 
recipients. However, the association of psychological flexibility (PF) with distress and HR-QOL in ICD 
recipients is yet to be examined.  
 
Aims  
The primary aim is to identify whether PF is associated with distress and HR-QOL in ICD recipients to 
determine if Acceptance and Commitment Therapy could be an indicated treatment for this population. 
The secondary aim is to determine socio-demographic, clinical and psychological variables associated 
with psychological distress and reduced HR-QOL in ICD recipients.  
 
Method 
A cross-sectional correlational design is proposed, with data being collected from ICD recipients’ post-
implantation. Participants will be recruited from multiple NHS clinics and using online and postal 
survey methods. Data on clinical, socio-demographic and psychological factors will be incorporated 
into a paper-based and online self-report questionnaire. Multivariate analysis is proposed. 
 
Applications  
Exploring the factors associated with distress and HR-QOL in ICD recipients may inform psychological 









Implantable cardioverter defibrillators (ICDs) are used in the treatment of life-threatening ventricular 
arrhythmias and in the prevention of sudden cardiac death. ICDs stop ventricular arrhythmias by 
delivering electrical shock to restore normal heart rhythm. ICDs are indicated for individuals at risk for 
ventricular arrhythmia (primary prevention) or those who have survived a life-threatening ventricular 
arrhythmia (secondary prevention).  
 
Benefits of ICDs are well-documented with research indicating they are more effective than 
pharmacological therapy at preventing sudden cardiac death (Ezekowitz, Armstrong & McAlister, 
2003). The ICD is accepted by most patients; however, approximately 25-33% experience 
psychological adjustment difficulties and impaired HR-QOL (Pedersen et al., 2005).  
 
Factors associated with increased distress and reduced HR-QOL in ICD recipients include being female; 
not being in a relationship; and being younger than fifty (Kajanova, Bulava & Eisenberger, 2014). 
Clinical factors, including past psychotropic medication use and the reason for ICD implant (primary 
versus secondary prevention), are risk factors for poorer adjustment (Kajanova, Bulava & Eisenberger, 
2014). Primary prevention ICD recipients have reported heightened anxiety and reduced HR-QOL 
compared to secondary prevention patients (Rahmawati et al., 2016). It is hypothesised secondary 
prevention recipients appraise their risk of cardiac death as higher due to previous experience and 
therefore view their ICDs as lifesaving. Conversely, primary prevention patients have not experienced 







Other clinical variables, including the number of device shocks received are associated with increased 
distress and reduced HR-QOL (Pedersen et al., 2005). The experience of device shock can be 
distressing, and the physical sensations caused by the discharge have been likened to a kick in the chest. 
This experience can lead to a conditioned response marked by avoidance of activities associated with 
ICD shock, fuelled by anticipatory anxiety of receiving shocks (Sears & Conti, 2002).  
 
The time since ICD implantation is also associated with adjustment, with depression and anxiety 
reducing over time. However, data on the length of the natural adjustment period are mixed. Some 
research indicates the 6-24 months post-implantation period as crucial for psychological adjustment 
(Petrowski et al., 2013) while other research reports difficulties resolve within the first few months 
post-implant (Kajanova, Bulava & Eisenberger, 2014). Consensus as to the length of the adjustment 
period will not be determined until prospective studies of psychological outcomes in ICD patients are 
conducted.   
 
Psychological explanations have been posed for patient variations in post-implant psychological 
adjustment. According to the Self-Regulation Model, adaptation to a health condition is an intricate 
self-regulation process (Leventhal, Meyer & Nerenz, 1980). Researchers hypothesise individuals 
develop cognitive illness representations, which assist them to understand their condition (Leventhal, 
Meyer & Nerenz, 1980). Using these representations, individuals develop coping responses to manage 
their condition. 
 
In ICD recipients, illness perceptions including lower perceived control of health status are associated 
with increased distress and reduced HR-QOL (Hammash et al., 2018). Additional research has 
identified ICD-specific psychological factors which predict maladjustment. For example, ICD-related 
concerns (worry about the ICD discharging) is an independent determinant of distress after controlling 
for the number of shocks received (Pedersen et al., 2005). 
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Perceptions of control and ICD-related concerns have implications for the design of psychological 
interventions. For example, CBT-based treatments can promote adaptive illness perceptions. 
Alternatively, change can be achieved by enabling individuals to ‘let go’ of the notion that everything 
is controllable, through acceptance-based interventions (Aujoulat et al., 2008). Acceptance-based 
strategies may be useful for ICD recipients given device shocks are uncontrollable.   
 
Acceptance-Based Approaches  
Acceptance strategies are components of interventions including Acceptance and Commitment Therapy 
(ACT). Acceptance-based interventions have advantages over other models in the context of chronic 
physical health conditions because illness perceptions including perceived control may be realistic in 
conditions where recovery is not possible (Angiola & Bowen, 2013). In ACT, the proposed mechanism 
of change is Psychological Flexibility (PF) which is conceptualised as being “mindful of experiences 
in the present moment, in an accepting and non-judgmental way, while behaving consistently with one’s 
values, even when one’s thoughts and feelings oppose taking valued actions” (Levin et al., 2014, p. 21). 
 
Targeting levels of PF may be of utility in ICD patients. Some ICD recipients avoid daily activities due 
to fear of receiving device shock (McCaig et al., 2014). Avoidance of valued activities relates to 
adjustment and remaining active despite health difficulties is recommended for well-being. ACT aims 
to foster PF, and to engage with valued actions in the face of distressing thoughts/feelings, which may 
be a useful strategy to target ICD-related avoidance patterns.  
 
No research was identified investigating PF in ICD recipients. Research has investigated PF in other 
health conditions, with higher levels of PF predicting lower levels of anxiety in those with cancer 






The primary aim is to determine whether PF is associated with distress and HR-QOL in ICD recipients 
to identify whether ACT could be an indicated treatment for this population. The secondary aim is to 
identify the socio-demographic, clinical and psychological variables associated with distress and HR-
QOL in ICD recipients.  
  
Hypotheses: 
H1 Lower PF will be associated with greater psychological distress and reduced HR-QOL in ICD 
recipients. 
 
H2 Socio-demographic variables (younger age >50, female sex, and single marital status) will be 
associated with psychological distress and HR-QOL in ICD recipients.  
 
H3 Clinical variables (number of shocks received, ICD indication, psychotropic medication use, and 
time since implant) will be associated with psychological distress and HR-QOL in ICD recipients. 
 
H4 Psychological factors including illness perceptions (perceived control) and ICD related concerns will 
be associated with psychological distress and HR-QOL in ICD recipients.  
 
H5 ICD related concerns will be independently associated with psychological distress in ICD recipients 















Plan of Investigation 
 
Participants  
ICD recipients will be recruited from NHS sites including Glasgow Royal Infirmary, Queen Elizabeth, 
Golden Jubilee Hospital and at clinics within the NHS Ayrshire & Arran board area.  
 
Inclusion Criteria  
• Individuals >18 years old. 
• Patients who have had an ICD implanted due to experiencing arrhythmias or heart failure. 
• Patients who have had their ICD >2 months.  
• Sufficient command of the English language to give consent and meaningfully participate.  
 
Exclusion Criteria  
• Individuals unable to complete the study due to experiencing significant cognitive impairment 
(Dementia, Learning Disability).  
• Individuals on the waiting list for heart transplantation.  












Recruitment & Research Procedures  
Participants will be recruited by the principal researcher or cardio-physiologists at post-implantation 
clinics. Those who meet eligibility criteria and provide informed consent will be asked to complete 
paper-based questionnaires or an online response using the NHS GGC survey tool: Webropol. It is 
estimated 40 ICD-recipients per week attend follow-up at Glasgow Royal Infirmary and there are 
approximately 180 patients attending clinics within NHS Ayrshire and Arran.  
 
Permission will also be sought to identify participants from an ICD-implant patient database stored at 
the Golden Jubilee Hospital. This database contains patients name, CHI number and date of ICD 
implantation. It is proposed the lead clinician will facilitate access to this database because they are part 
of the clinical team. The lead clinician will then obtain patients address details by entering individuals 
CHI number into electronic record systems. The principle researcher will print out packs containing 
participant information sheets, consent forms, and paper-based questionnaires with only members of 
the clinical team attaching patients address details to the packs.  
 
Participants will then be mailed a study information sheet, information on inclusion/exclusion criteria, 
consent form, paper copies of questionnaires and a survey link to access online version of the survey. 
Participants completing the online survey, will be asked to indicate whether they have any of the 
conditions outlined in the exclusion criteria. If participants meet exclusion criteria they will be screened 
out of the survey and thanked for their interest.  
 
Participants choosing to complete paper-based questionnaires will be asked to withdraw if they have 
any of the conditions mentioned in the exclusion criteria. Participants will be provided with a pre-paid 
envelope to enable them to return their consent forms and completed paper-questionnaires. Previous 






Socio-demographic information including sex, age, marital status and educational level will be 
collected by self-report. Clinical variables including time since implant, number of shocks experienced, 
information on primary vs secondary indication for ICD-implantation, heart failure or fibrillation 




Psychological distress will be measured with the Hospital Anxiety and Depression Scale (HADS; 
Zigmond & Snaith, 1983). The HADS contains 14-items, 7 of which measure depression (HADS-D), 
and 7 measure anxiety (HADS-A). Items are scored on a 4-point Likert scale. Scores range from 0 to 
3, with a total score of 0–21 for each subscale. Research suggests employing a cut-point of > 8 for each 
of the constituent subscales, to indicate probable caseness. This cut-off provides sensitivity and 
specificity of 0.80 (Bjelland et al., 2002). The Cronbach's alpha values are 0.83 and 0.82 for the HADS-




The EuroQol-5D-3 level (EQ-5D-3L) assesses five domains of HR-QOL: mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression (EuroQol Group, 1990). Items are scored on a three-
point scale, ranging from 1 (no problems) to 3 (severe problems). There is a total of 243 health status 
combinations, each of which are referred to using a five-digit code, using the numbers 1 to 3. Once 
established the five-digit code can be transformed into a single mean index score, with 1.0 representing 
full health and -0.59 indicating the lowest index. Research supports the validity and reliability of the 





Psychological Flexibility  
The Cardiovasular Disease Acceptance and Action Questionnaire (CVD-AAQ) is an adaptation of a 
general measure of PF, the AAQ. The CVD-AAQ measures acceptance of thoughts and feelings related 
to cardiovascular illness and the degree to which these internal events interfere with individuals’ ability 
to engage in valued action. The Italian version of the CVD-AAQ indicated fair reliability with a 
Cronbach’s alpha of 0.75 (Spatola et al., 2014).  
 
ICD-Related Concerns  
 
Device related concerns will be measured with the Patient ICD-related Concerns (ICDC) questionnaire 
(Pedersen et al., 2005). The ICDC contains 8-items that are rated on a 5-point Likert scale from 0 (not 
at all) to 4 (very much so). Scores range from 0 to 32, with higher scores indicating more ICD-related 
concerns. There is no standardised cut-off for the ICDC; however, research propose dividing patients 
into a low versus high concern group, using the cut-off of >13 to indicate high concerns (Pedersen et 
al., 2005). The internal consistency of the ICDC is good with a Cronbach’s alpha of 0.91.  
 
Illness Perceptions  
 
The Brief Illness Perception Questionnaire (B-IPQ) measures illness perceptions (Broadbent et al., 
2006). The B-IPQ contains 9-items and is rated on a 0-10 Likert scale, which assesses cognitive illness 
perceptions, emotional (illness concerns), illness comprehensibility and causal representations. Scores 
range from 0 to 80, with a higher score reflecting a more threatening view of illness. Correlation 
coefficients of items in a test of test-retest reliability were r = .88 in a sample of cardiac patients 










A cross-sectional correlational design is proposed. Data will be collected from ICD recipients at one 
time point (post-implantation). 
Data Analysis 
Descriptive statistics will be calculated to summarise the independent variables (clinical, psychological 
and socio-demographic characteristics) and the outcome variables (HADS and Euro-QOL scores).  
Univariate analyses between the independent and outcome variables will be assessed using Pearson’s 
correlation co-efficient or independent sample t-tests depending on the level of measurement of the 
variables, in determining candidate explanatory variables for regression analysis.  
Linear multiple regression will be used to test hypothesis 1, 2, 3 and 4 by identifying what independent 
variables are predictors of distress and HR-QOL.  
Hierarchical regression analysis will be used to test hypothesis 5 to determine whether ICD related 
concerns are independently associated with symptoms of anxiety/depression despite controlling for 













Sample Size  
Recommendations for conducting regression analysis stipulates a sample of 10-15 participants per 
predictor. Prior research investigating whether PF is associated with distress in ICD-recipients was not 
identified. Nevertheless, research has reported PF predicted levels of anxiety and depression in a sample 
of individuals with cancer, with moderate effect sizes (r2 = .43) (Montiel et al., 2016). G* Power was 
used to estimate sample size and indicated a required sample of 47 participants to conduct multiple 
regression based on a moderate predicted effect size (f2 = 0.75), with 12 predictors (α = 0.05, β = 0.95). 
 
However, research investigating variables including the relationship between ICD-related concerns and 
HR-QOL have reported small effect sizes (r2 = .093) (Thylén et al., 2014).  Based on a small predicted 
effect size (f2 = .1), G* Power indicated a required sample of 185 to conduct multiple regression, with 
12 predictors (α = 0.05, β = 0.80). Accordingly, the study will aim to recruit 185 participants. 
 
 
Settings and Equipment  
 
Data collection will occur in clinic-based settings, with participants completing measures in waiting 
areas or a private room if available. Required equipment includes paper copies of the questionnaires, 
access to the Webropol survey tool, and a secure cabinet and or encrypted laptop/computer to store data 
and record participants responses if completing the online survey. Other equipment includes SPSS and 














Health and Safety Issues 
The researcher will observe the recruitment sites’ health and safety procedures. The research will not 
involve making diagnosis of mental health problems. Nevertheless, participants will be sign-posted to 
their GP if they have any concerns about their physical or mental well-being. Information sheets and 





The project aims to recruit NHS patients at sites including Glasgow Royal Infirmary, Queen Elizabeth 
University Hospital, clinics within NHS Ayrshire & Arran and from the Golden Jubilee Hospital ICD 
implantation database. Accordingly, an ethics application will be submitted to the NHS ethics 
committee and relevant NHS health boards’ R&D for approval.   
 
Informed Consent  
For participants recruited at clinics, consent will be facilitated by providing individuals with an 
information sheet and consent form and where feasible, the study will be explained verbally by the 
principal researcher or cardio-physiologists. Participants will be informed their choice to decline or 
participate will not affect their medical care and that they have the right to withdraw. All participants 
will be asked if they consent to be contacted regarding future research.  
 
For participants choosing to complete the measures using the online survey tool, the information sheet 
and consent form will be displayed electronically. At the end of the online survey, participants will be 
asked if they consent to submit their response and will be informed, they are not obliged to do so. At 
this stage, participants will be informed they will not be able to withdraw their data once submitted 
because the data will be anonymised.  
 155 
For participants recruited via postal methods, consent will be indicated by their return of completed 
consent forms and questionnaires. All postal participants will be informed they have the right to decline 
the survey invitation.  
 
Confidentiality  
To ensure confidentiality, participants’ responses will be anonymised and will be stored in a password 
protected data file. Signed consent forms will be stored in a locked cabinet separate from respondents’ 
questionnaire responses. For participants who consent to be contacted regarding future research, their 
contact details will be stored in a password protected data-file on an encrypted device. Data will be 
stored in accordance with the Data Protection Act 2018. 
Risks 
Risks to participants include the identification of symptoms of anxiety/depression through their HADS 
scores. To ensure participants’ safety, the information sheet will provide information on assessing 
supports by directing them to their GP and providing contact details for NHS 24, the Samaritans and 
Breathing Space. Additionally, for participants choosing to complete an online response a debrief page 
will be displayed at the end of the survey. The debrief page will encourage participants to seek a GP 
appointment if concerned about their well-being and provide information on supports including NHS 










All measures are available for use without purchase or consent has been obtained for their use. An 
encrypted laptop will be borrowed from University of Glasgow. Printing, photocopying and pre-paid 
postage costs will be incurred (See Appendix 2).  
Timetable 
 
Proposal  16th December 2019  
Ethics Application January – March 2020 
Data Collection  April – October 2020 
Data Analysis & Write up  November – February 2021 




Identifying factors associated with distress and HR-QOL in ICD recipients could elucidate 
characteristics of patients at risk of developing post-implant adjustment issues. Additionally, the 
identification of psychological variables associated with distress can aid identification of modifiable 
factors to be targeted within psychological therapy. Finally, the study may be the first to investigate 
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Appendix 2.2 Summary of Project Protocol   
 
Title: Trajectories of Anxiety, Depression and Health-Related Quality of Life in 
Patients with Chronic Heart Failure 
 
Lead author: Claire Davidson (Trainee Clinical Psychologist)  
University Supervisors: Professor Hamish McLeod, Dr Katie Robb   
Field Supervisor: Dr John Sharp  
Study Type: Data Only  
  
IRAS Reference: 291895  
  
R&D Reference: GN20MH589  
 
Background    
Psychological adjustment to Chronic heart failure (CHF) can be challenging. A meta-analysis indicated 
the prevalence rate of depression was 21.5% in CHF patients, with the estimates differing depending 
on the use of diagnostic interview versus self-report questionnaires (19.3% and 33.6% respectively) 
(Rutledge et al., 2006). Additionally, a systematic review and meta-analysis reported a pool prevalence 
of 13.1% for anxiety disorders in people with CHF (Easton et al., 2016).  
 
Additionally, research has shown individuals with CHF experience reduced health related quality of 
life (HR-QOL) compared with individuals with other health problems including 
chronic hemodialysis (Juenger et al., 2002). The relationship between co-occurring emotional distress 
in CHF patients and HR-QOL has been investigated in the literature. Individuals with depression self-
report higher functional impairment and lower HR-QOL compared with people without depression and 
individuals with higher New York Heart Association (NYHA) severity of HF symptoms 
classification (Sullivan et al., 2004).   
 
A body of research has investigated factors which predict the development of anxiety, and depression 
in individuals with CHF. Some data have indicated that the development of depression appears to be 
associated with periods of acute worsening of HF symptoms (Johansson et al., 2013). Variance in 
depression and anxiety in individuals with CHF has also been associated with social-demographic 
factors (sex, age, socio-economic status), social factors (level/quality of social support), clinical factors 
(NYHA class) and psychological factors (coping styles) (Haworth et al., 2005; Lerdal et al., 2019). 
 
Trajectories over time   
   
Although a body of cross-sectional research has examined psychological adjustment and the associated 
factors/predictors in individuals with CHF, there has been limited research investigating the 
longitudinal trajectories of anxiety, depression and HR-QOL in patients with HF (Dekker et al., 2011; 
Johansson et al., 2013).   
   
Previous HF research has indicated the severity of depression might vary or improve over time 
(Johansson et al., 2013). Conversely, others suggest mental health symptoms such as depression can 












There has been limited research examining and describing the trajectories of anxiety in individuals with 
CHF. It is important to explore how anxiety and depression in people with CHF develops over time to 
identify whether anxiety/depression symptoms are transient or whether difficulties in these areas follow 
a more persistent course. 
 
Aims of the study:    
  
1. To examine the trajectories of anxiety, depression, and HR-QoL in a sample of patients with 
heart failure over 24-month follow-up period.     
  
2. To explore the predictors of these trajectories, using clinical, demographic and social factors    
  
 
Statistical Analysis Plan   
  
Data Source: The proposed study will be a secondary analysis of data collected as part of a 
study examining palliative care needs in people with CHF (Campbell et al., 2018; REC Ref: 
12/WS/0224; IRAS Ref 100839). Patients recruited into the original study consented to 
their anonymised data being analysed in future research. The design and rationale of the 
original study have been published elsewhere (Campbell et al., 2015) and involved a consecutively 
recruited cohort of HF patients admitted for hospital care and then followed up over 2 or 3 data 
collection waves. Eligible patients were aged over 18 years and met the following inclusion criteria:   
 
Admitted to hospital (from 9th January 2013 to 1st December 2014) with a primary diagnosis of acute 
decompensated HF  
Fulfilling the ESC diagnostic criteria for the diagnosis of HF  
HF-REF, HF-PEF and valvular HF will be included.  
  
The exclusion criteria were:   
- Refusal to participate  
- Unable to provide informed consent/ complete study assessments  
- Confusion/ dementia  
- Learning difficulties  
- Unable to read or write English language   
- Moribund  
- Geographical reasons, not from catchment area  
- Isolated cor pulmonale  
- Acute coronary syndrome complicated by pulmonary oedema  
  
All patients from the original study were eligible for inclusion in this secondary data analysis study 
(dependent on data completeness). The full data set is expected to comprise up to the 272 participants 
who were assessed in the original study.   
 
The Robertson Centre for Biostatistics will be consulted during the execution of the statistical 
analysis plan. The plan for the first wave of data analysis is as follows:    
  
Patients who provided at least one measurement of anxiety or depression (HADS) and HR-QOL 
measurements during the two-year follow-up period will be included in the analysis. Descriptive 
statistics will be run to indicate the number of patients with missing HADS and HR-QOL scores across 
baseline measures, and the 4, 8, 12, 16, 20- and 24-month follow-up measurements.   
  
Patient characteristics will be summarised using means, medians, standard deviations or frequency 
distributions. Key descriptive statistics will be calculated for the primary outcome measures. The 
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standard HADS cut off point of ≥8 would be used to categorise individuals' as having clinically 
significant anxiety/depression symptoms at baseline and subsequent follow-up measurements.    
 
Using an approach described in previous research (e.g., Decker et al., 2011) individuals will then 
be categorised into four symptom status groups based on change of HADS score or lack of significant 
change in HADS score from baseline to follow-up measurements:    
  
1. No clinically significant anxiety/depression    
2. Anxiety/depression improved    
3. Anxiety/depression developed    
4. Persistent anxiety/depression   
 
 
Exploring baseline and follow-up measurements of anxiety and depression scores being using suitable 
regression models. This phase will involve a start and end point analysis plan. For 
example, the measurement between baseline (start) and one follow-up measurement (end point) will be 
explored at a time (e.g., at 4 months point, or 12 months (as an end point). The 
proposed regression analysis will adjust for, important variables. 
  
If feasible and the data allows:   
  
The trajectory of anxiety and depression symptoms amongst the four groups, will 
be analysed with repeated measures analysis of variance with Tukey honestly significant difference 
(HSD) post-hoc tests (following the approach of Decker et al., 2011). Nevertheless, if there is 
significant amount of missing data between follow-up measurements, the data will 
be analysed using linear mixed effects models.    
  
Univariate analyses will also examine the relationship between each of the candidate predictor variables 
(e.g., symptom burden), social support access (marital status as a proxy measure) and the outcome 
variables (HADS score, HR-QOL scores (measured by SF-12 & Kansas Heart Failure Questionnaire). 
This will be assessed using Pearson’s correlation co-efficient or independent sample t-tests depending 
on the level of measurement of the variables, in determining candidate explanatory variables for 
regression analysis.   
  
Multivariate Analysis    
Descriptive statistics to examine kurtosis and skew should be used to evaluate the normality 
of continuous outcomes prior to conducting multivariate analysis. If the data is not normal an attempt 
will be made to statistically transform the data. Provided assumptions are met, we will conduct Latent 
Class Analysis. Latent class analysis (Latent Gold) could be used to identify how many latent classes 
(i.e., trajectories of anxiety, depression and HR-QOL) can be described.   
  
Data management:   
Data will only be accessed and processed on the Robertson Centre for Biostatistics analytic platform 
via a secure remote access web portal. Data access will be restricted to Claire Davidson (the doctoral 
research student). All data are in anonymised form and will remain so for the purposes of analysing, 
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Appendix 2.3 Overview of Author’s Intellectual Input into the Alternative Project   
 
 
• Reviewed the heart failure literature to formulate research questions.  
• Completed a project proposal and provisional statistical analysis plan.  
• Screened and cleaned secondary quantitative data.  
• Restructured format of data to answer the primary research questions.   
• Statistical analysis – conducted statistical tests. Adapted statistical analysis plan due to 
missing data.  
• Interpreted results from data outputs and discussed outcomes with research supervisors.  
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Appendix 2.5 Table 5 and 6 Characteristics of Participants who Completed Anxiety and Depression Measures  
 
Table 5. Characteristics of Participants Who Completed 1, 2, 3 or 4 Assessments of Anxiety  
Characteristics Participants with four 
anxiety measures 
(baseline, 4, 8 and 12-
months) 
 
N = 92 
Participants with 
three anxiety 
measures (baseline, 4, 
and 8-months) 
 
N = 37 





N = 42 




N = 62 
P value 
Age 75.42 (70.37, 83.05) 76.22 (69.33, 85.12) 79.45 (73.01, 85.73) 77.39 (72.14, 82.77) .364 
 
Female Sex  45 (48.9%) 17 (45.9%) 21 (50.0%) 36 (58.1%) .616 



















































































burden score  
 
38.00 (22.00, 51.50) 34.44 (17.78, 58.39) 39.50 (28.05, 58.50) 36.00 (16.00, 58.89) .758  
HF diagnosis prior to 
index admission 





















AF history 51 (55.4%) 20 (54.1%) 19 (45.2%) 36 (58.1%) .618 
MI history 39 (42.4%) 9 (24.3%) 21 (50.0%) 31 (50.0%) .061 
History of arrhythmia 7 (7.6%) 4 (10.8%) 4 (9.5%) 5 (8.1%) .937 
Current Depression 
 
Depression at baseline 
(HADS-D ≥8) 
 





























Depression history 12 (13.2%)† 8 (23.5%)† 5 (11.9%)† 8 (12.9%) .570 
Anti-depressant use 
  








































































Note: Categorical variables are denoted as N and (%) Continuous variables are represented by Median and (Interquartile Range). P values were calculated using Mann Whitney U test for non-normally distributed 
continuous variables and the chi-square test of association for categorical variables. If the frequency in a cell was <5, p-values were calculated using Fishers exact probability test. For variables with a 2 by 2 table 
Yates’ Correction for Continuity value is presented. Bolded values highlight statistically significant differences. † Denotes that valid percentages are reported. Abbreviations: NYHA = New York Heart Association, 
HF = heart failure, AF = atrial fibrillation, MI = myocardial infarction, COPD = chronic obstructive pulmonary disease, HADS = hospital anxiety and depression scale
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Table 6. Characteristics of Participants Who Completed 1, 2, 3 or 4 Assessments of Depression   
 
Characteristics Participants with 
four depression 
measures (baseline, 
4, 8 and 12-months) 
 




(baseline, 4, and 
8-months) 
 
N = 43 





N = 43 
Participants with one a 
measure (baseline only) 
 
 N = 57  
p value 
Age (years) 74.35 (70.20, 82.27) 80.37 (70.90, 
85.23) 
79.38 (73.43, 84.15) 78.21 (72.23, 84.12) .111 
Female Sex  41 (43.2%) 22 (51.2%) 23 (53.5%) 36 (63.2%) .121 





















































































36.00 (20.00, 50.00) 38.00 (19.00, 
59.00) 
43.00 (31.11, 60.00) 38.33 (18.89, 59.17) .578  
HF diagnosis prior to 
index 



















AF history 53 (55.8%) 20 (46.5%) 20 (46.5%) 32 (56.1%) .582 
MI history 39 (41.1%) 14 (32.6) 23 (53.5%) 24 (42.1%) .268 
History of arrhythmia 8 (8.4%) 4 (9.3%) 5 (11.6%) 4 (7.0%) .864 
Current Depression 
 
Depression at baseline 
(HADS-D ≥8) 
 





































Depression history 15 (15.8%) 8 (18.6%) 5 (11.6%) 7 (12.3%) .741 








































































Note: Categorical variables are denoted as N and (%) Continuous variables are represented by Median and (Interquartile Range). P values were calculated using Mann Whitney U test for non-normally distributed 
continuous variables and the chi-square test of association for categorical variables. If the frequency in a cell was <5, p-values were calculated using Fishers exact probability test. For variables with a 2 by 2 table 
Yates’ Correction for Continuity value is presented. Bolded values highlight statistically significant differences. † Denotes that valid percentages are reported. Abbreviations: NYHA = New York Heart Association, 
HF = heart failure, AF = atrial fibrillation, MI = myocardial infarction, COPD = chronic obstructive pulmonary disease, HADS = hospital anxiety and depression scale.
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Appendix 2.6 Histograms of Participants Anxiety and Depression Scores 
 171 
 
 
